

English Translation of Financial Statements and a Report Originally Issued in Chinese

GRAPE KING BIO LTD.
CONSOLIDATED FINANCIAL STATEMENTS
WITH REPORT OF INDEPENDENT ACCOUNTANTS
AS OF MARCH 31, 2018 AND 2017
AND FOR THE THREE-MONTH PERIODS THEN ENDED
(REVIEWED BUT UNAUDITED)

Address: No.402, Sec. 2, Jinling Rd., Pingzhen Dist., Taoyuan City 324, Taiwan (R.O.C.)
Telephone: 886-3-457-2121

The reader is advised that these consolidated financial statements have been prepared originally in Chinese. In the event of a conflict between these financial statements and the original Chinese version or difference in interpretation between the two versions, the Chinese language financial statements shall prevail.

English Translation of a Report Originally Issued in Chinese
REVIEW REPORT OF INDEPENDENT ACCOUNTANTS

To: Grape King Bio Ltd.

Introduction

We have reviewed the accompanying consolidated balance sheets of Grape King Bio Ltd. (the “Company”) and its subsidiaries as of March 31, 2018 and 2017, the related consolidated statements of comprehensive income, changes in equity and cash flows for the three-month periods then ended, and notes to the consolidated financial statements, including the summary of significant accounting policies (together “the consolidated financial statements”). Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and International Accounting Standard 34, “Interim Financial Reporting” as endorsed and became effective by Financial Supervisory Commission of the Republic of China. Our responsibility is to express a conclusion on these consolidated financial statements based on our reviews.

Scope of Review

We conducted our reviews in accordance with Statement of Auditing Standards No. 65, “Review of Financial Information Performed by the Independent Auditor of the Entity” of the Republic of China. A review of consolidated financial statements consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with auditing standards generally accepted in the Republic of China and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion

Based on our reviews and the review reports of other independent accountants (please refer to the Other Matter paragraph of our report), nothing has come to our attention that causes us to believe that the accompanying consolidated financial statements do not present fairly, in all material respects, the consolidated financial position of the Company and its subsidiaries as of March 31, 2018 and 2017, and their consolidated financial performance and cash flows for the three-month periods then

(To be continued)

(Continued)


ended, in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and International Accounting Standard 34, “Interim Financial Reporting” as endorsed and became effective by Financial Supervisory Commission of the Republic of China.

Emphasis of Matter – Applying for New Accounting Standards

We draw attention to Note 3 of the consolidated financial statements, which describes the Company and its subsidiaries applied for the International Financial Reporting Standard 9, “Financial Instruments” and 15, “Revenue from Contracts with Customers” starting from January 1, 2018, and elected not to restate the consolidated financial statements for prior periods. Our conclusion is not modified in respect of this matter.

Other Matter – Making Reference to the Reviews of Other Independent Accountants

We did not review the financial statements of Pro-partner Inc., a 60%-owned subsidiary of the Company, while they were reviewed by the other auditors, which statements reflect total assets of NT\$5,159,705 thousand and NT\$5,217,397 thousand, constituting 51.41% and 54.70% of consolidated total assets as of March 31, 2018 and 2017, respectively, and total operating revenues of NT\$1,584,326 thousand and NT\$1,841,981 thousand, constituting 81.99% and 91.92% of consolidated operating revenues for the three-month periods then ended, respectively. Those financial statements were reviewed by other independent accountants, whose reports thereon have been furnished to us, and our review results with respect to Pro-partner Inc. are based solely on the reports of the other independent accountants.



ERNST & YOUNG

May 7th, 2018

Taipei, Taiwan,

Republic of China

Notices to Readers

The accompanying consolidated financial statements are intended only to present the consolidated financial position, results of operations and cash flows in accordance with accounting principles and practices generally accepted in the Republic of China and not those of any other jurisdictions. The standards, procedures and practices to review such consolidated financial statements are those generally accepted and applied in the Republic of China.

English Translation of Consolidated Financial Statements Originally Issued in Chinese

GRAPE KING BIO LTD.

CONSOLIDATED BALANCE SHEETS

As of March 31, 2018, December 31, 2017 and March 31, 2017 (March 31, 2018 and 2017 are Reviewed but Unaudited)

(Amounts Expressed in Thousands of New Taiwan Dollars)

Assets	Notes	As of			Liabilities and Stockholders' Equity	Notes	As of		
		March 31, 2018	December 31, 2017	March 31, 2017			March 31, 2018	December 31, 2017	March 31, 2017
Current assets					Current liabilities				
Cash and cash equivalents	3,4,6(1)	\$1,993,698	\$1,920,497	\$1,938,102	Short-term debt	4,6(14),8	\$450,000	\$300,000	\$-
Financial assets at fair value through profit or loss	3,4,6(2)	170,465	70,376	240,186	Contract liabilities	3,6(23)	78,502	-	-
Financial assets measured at amortized cost	3,4,6(5)	43,535	-	-	Notes payable		2,775	7,207	1,480
Debt investments without active market	3,4,6(6)	-	180,075	42,335	Accounts payable		166,695	316,108	172,736
Notes receivable, net	3,4,6(7)	3,149	5,753	4,133	Accounts payable-related parties	7	-	-	115
Accounts receivable, net	3,4,6(8)	103,117	154,616	160,070	Other payables	6(15)	1,333,873	1,618,259	1,351,275
Accounts receivable-related parties, net	3,4,6(8),7	-	-	159	Other payables-related parties	7	39,383	32,773	39,847
Other receivables	3,4	2,761	6,111	3,922	Current tax liabilities	4,6(27)	329,934	250,431	358,602
Inventories, net	4,6(9)	442,879	492,058	452,223	Other current liabilities	6(9)(16)	51,607	151,078	244,682
Prepayments	6(10)	50,285	48,892	42,747	Current portion of bonds payable	4,6(17)	113,355	171,207	-
Other current assets	6(10)	15,056	11,643	6,318	Current portion of long-term loans payable	4,6(18),8	31,942	31,974	51,742
Total current assets		2,824,945	2,890,021	2,890,195	Total current liabilities		2,598,066	2,879,037	2,220,479
Non-current assets					Non-current liabilities				
Financial assets at fair value through profit or loss	3,4,6(2),15	-	-	139	Bonds payable	4,6(17)	-	-	169,794
Financial assets at fair value through other comprehensive income	4,6(3)	16,664	-	-	Long-term debt	4,6(18),8	510,661	518,670	929,089
Financial assets measured at amortized cost	3,4,6(5),8	4,460	-	-	Deferred tax liabilities	4,6(27)	68,463	68,463	69,272
Financial assets measured at cost	3,4,6(4)	-	28,028	28,028	Other liabilities	6(19)	96,214	97,514	100,502
Debt investments without active market	3,4,6(6),8	-	4,460	4,460	Total non-current liabilities		675,338	684,647	1,268,657
Property, plant and equipment	4,6(11),8	6,435,257	6,355,416	6,144,222	Total liabilities		3,273,404	3,563,684	3,489,136
Investment properties	4,6(12)	185,985	185,985	185,985	Equity attributable to the parent company	6(22)			
Intangible assets	4,6(13)	20,781	22,442	25,195	Capital				
Deferred tax assets	4,6(27)	5,522	5,752	20,724	Common stock		1,355,866	1,352,211	1,352,142
Other assets-others	6(10)	541,841	399,552	239,658	Additional paid-in capital	6(17)(22)	855,162	800,246	799,221
Total non-current assets		7,210,510	7,001,635	6,648,411	Retained earnings	6(22)			
					Legal reserve		675,213	675,213	545,536
					Special reserve		74,671	74,671	74,671
					Unappropriated earnings		2,678,883	2,418,570	2,321,471
					Other components of equity		(34,883)	(34,603)	(50,131)
					Treasury stock	6(22)	(91,062)	(91,062)	(91,062)
					Non-controlling interests	6(23)(29)	1,248,201	1,132,726	1,097,622
					Total equity		6,762,051	6,327,972	6,049,470
Total assets		\$10,035,455	\$9,891,656	\$9,538,606	Total liabilities and equity		\$10,035,455	\$9,891,656	\$9,538,606

The accompanying notes are an integral part of the consolidated financial statements.

English Translation of Consolidated Financial Statements Originally Issued in Chinese

GRAPE KING BIO LTD.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

For the three-month periods ended March 31, 2018 and 2017 (Reviewed but Unaudited)

(Amounts Expressed in Thousands of New Taiwan Dollars, Except for Earnings per Share)

	Notes	For the three-month period ended March 31,	
		2018	2017
Operating revenues	3,4,6(23),7	\$1,932,426	\$2,003,929
Operating costs		(392,162)	(264,573)
Gross profit		1,540,264	1,739,356
Operating expenses	7		
Selling and marketing	3	(940,111)	(1,158,567)
General and administrative		(99,257)	(97,376)
Research and development		(41,111)	(36,345)
Operating expenses total		(1,080,479)	(1,292,288)
Operating income		459,785	447,068
Non-operating income and expenses			
Other incomes	6(25),7	20,445	20,207
Other gains and losses	6(25)	(1,870)	(1,347)
Finance costs	6(25)	(3,838)	(4,414)
Non-operating income and expenses total		14,737	14,446
Income from continuing operations before income tax		474,522	461,514
Income tax expense	4,6(27)	(98,734)	(80,004)
Net income		375,788	381,510
Other comprehensive income (loss)	6(26)		
Items that will not be reclassified subsequently to profit or loss			
Unrealized gains or losses on financial assets at fair value through other comprehensive income (loss)		(1,723)	-
Income tax related to items that will not be reclassified subsequently		-	-
Items that may be reclassified subsequently to profit or loss			
Exchange differences on translation of foreign operations		11,084	(23,927)
Income tax related to items that may be reclassified subsequently		-	-
Total other comprehensive income, net of tax		9,361	(23,927)
Total comprehensive income		\$385,149	\$357,583
Net income attributable to:			
Stockholders of the parent		\$260,313	\$258,825
Non-controlling interests	6(29)	115,475	122,685
		\$375,788	\$381,510
Total comprehensive income attributable to:			
Stockholders of the parent		\$269,674	\$234,898
Non-controlling interests	6(29)	115,475	122,685
		\$385,149	\$357,583
Earnings per share-basic (NTD)	6(28)	\$1.93	\$1.92
Earnings per share-diluted (NTD)	6(28)	\$1.92	\$1.90

The accompanying notes are an integral part of the consolidated financial statements.

English Translation of Consolidated Financial Statements Originally Issued in Chinese

GRAPE KING BIO LTD.

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY

For the three-month periods ended March 31, 2018 and 2017 (Reviewed but Unaudited)

(Amounts Expressed in Thousands of New Taiwan Dollar)

	Common Stock	Additional Paid-in Capital	Retained Earnings			Exchange Differences on Translation of Foreign Operations	Other Components of equity		Treasury stock	Non-Controlling Interests	Total Equity
			Legal Reserve	Special Reserve	Unappropriated Earnings		Unrealized Gains or Losses on Financial Assets Measured at Fair Value through Other Comprehensive Income	Total			
Balance as of January 1, 2017	\$1,352,142	\$799,221	\$545,536	\$74,671	\$2,062,646	\$(26,204)	\$-	\$-	\$4,808,012	\$974,937	\$5,782,949
Net income for the three-month period ended March 31, 2017					258,825				258,825	122,685	381,510
Other comprehensive income, net of tax for the three-month period ended March 31, 2017						(23,927)			(23,927)	-	(23,927)
Total comprehensive income	-	-	-	-	258,825	(23,927)	-	-	234,898	122,685	357,583
Treasury stock								(91,062)	(91,062)		(91,062)
Balance as of March 31, 2017	\$1,352,142	\$799,221	\$545,536	\$74,671	\$2,321,471	\$(50,131)	\$-	\$(91,062)	\$4,951,848	\$1,097,622	\$6,049,470
Balance as of January 1, 2018	\$1,352,211	\$800,246	\$675,213	\$74,671	\$2,418,570	\$(34,603)	\$-	\$(91,062)	\$5,195,246	\$1,132,726	\$6,327,972
Impact of retroactive applications	-	-	-	-	-	-	(9,641)	-	(9,641)	-	(9,641)
Adjusted balance as of January 1, 2018	1,352,211	800,246	675,213	74,671	2,418,570	(34,603)	(9,641)	(91,062)	5,185,605	\$1,132,726	\$6,318,331
Shares from bonds converted	\$3,655	\$54,916							\$58,571	-	\$58,571
Net income for the three-month period ended March 31, 2018					260,313				260,313	115,475	375,788
Other comprehensive income, net of tax for the three-month period ended March 31, 2018						11,084	(1,723)		9,361	-	9,361
Total comprehensive income	-	-	-	-	260,313	11,084	(1,723)	-	269,674	115,475	385,149
Balance as of March 31, 2018	\$1,355,866	\$855,162	\$675,213	\$74,671	\$2,678,883	\$(23,519)	\$(11,364)	\$(91,062)	\$5,513,850	\$1,248,201	\$6,762,051

The accompanying notes are an integral part of the consolidated financial statements.

English Translation of Consolidated Financial Statements Originally Issued in Chinese

GRAPE KING BIO LTD.

CONSOLIDATED STATEMENTS OF CASH FLOWS

For the three-month periods ended March 31, 2018 and 2017 (Reviewed but Unaudited)

(Amounts Expressed in Thousands of New Taiwan Dollars)

	For the three-month period ended March 31,			For the three-month periods ended March 31,	
	2018	2017		2018	2017
Cash flows from operating activities:			Cash flows from investing activities:		
Net income before tax	\$474,522	\$461,514	Acquisition of debt investments without active market	134,330	-
Adjustments to reconcile net income (loss) before tax to net cash provided by (used in) operating activities:			Dispose of debt investments without active market	-	1,050
Depreciation	57,527	53,061	Acquisition of property, plant and equipment	(346,245)	(254,313)
Amortization	1,742	1,592	Disposal of property, plant and equipment	23	-
Expected credit loss (gain)	(179)	28	Increase in refundable deposits	(3,334)	(951)
Net gain of financial assets at fair value through profit or loss	(111)	(160)	Acquisition of intangible assets	(81)	(152)
Interest expense	3,838	4,414	Other non-financial assets	10	239
Interest revenue	(1,809)	(995)	Net cash provided by (used in) investing activities	(215,297)	(254,127)
Loss from disposal of property, plant and equipment	81	373	Cash flows from financing activities:		
Changes in operating assets and liabilities:			Increase (decrease) in short-term loans	150,000	(50,000)
Financial asset held for trading	-	105,983	Repayment of long-term loans	(8,041)	(5,779)
Financial assets mandatorily measured at fair value through profit or loss	(99,984)	-	Increase (decrease) in deposits received	473	(203)
Notes receivable	2,604	965	Cost of Treasury stock	-	(91,062)
Accounts receivable	51,678	36,285	Net cash provided by (used in) financing activities	142,432	(147,044)
Accounts receivable-related parties	-	2,748	Effect of exchange rate changes on cash and cash equivalents	7,755	(10,610)
Other receivables	3,442	168	Net increase (decrease) in cash and cash equivalents	73,201	38,800
Inventories	49,179	(17,233)	Cash and cash equivalents at beginning of period	1,920,497	1,899,302
Prepayments	(1,774)	(7,483)	Cash and cash equivalents at end of period	\$1,993,698	\$1,938,102
Other current assets	(3,413)	(582)			
Contract liabilities	(4,583)	-			
Notes payable	(4,432)	(9,855)			
Accounts payable	(149,413)	(14,001)			
Accounts payable-related parties	-	115			
Other payables	(209,021)	(222,411)			
Other payables-related parties	6,610	6,768			
Other current liabilities	(16,974)	65,883			
Accrued pension liabilities	(916)	(6,179)			
Cash generated from operations	158,614	460,998			
Interest received	1,717	961			
Interest paid	(3,019)	(3,602)			
Income tax paid	(19,001)	(7,776)			
Net cash provided by (used in) operating activities	138,311	450,581			

The accompanying notes are an integral part of the consolidated financial statements.

Grape King Bio Ltd.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(REVIEWED BUT UNAUDITED)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

1. History and organization

Grape King Bio Ltd. (The Company) was incorporated as a listed company limited by shares under the provisions of Company Act, the Securities and Exchange Act and other related regulations of the Republic of China (R.O.C.). In April 1971, the Company was officially registered as "Grape King Food Limited" and started its operation. In 1979, the Company merged with "China Fuso Seiko Pharmaceutical Industries Ltd." and was renamed as "Grape King Inc." In 1981, the Company further merged "Head Fancy Cosmetics Co. Ltd." The Company's stocks were listed and publicly traded on the Taiwan Stock Exchange (TWSE) starting December 1982. In the annual shareholders' meeting held on June 12, 2002, the Company resolved to change its name for "Grape King Bio Ltd". The Company is engaged in the production and sales of pharmaceutical preparation, patent medicine, liquid tonic, drink, healthy food, etc. The Company's registered office and main business location is at No.402, Sec. 2, Jinling Rd., Pingzhen Dist., Taoyuan City 324, Taiwan, Republic of China.

2. Date and procedures of authorization of financial statements for issuance

The consolidated financial statements of the Company and its subsidiaries ("the Group") for the three-month periods ended March 31, 2018 and 2017 were authorized for issuance at May 7, 2018 by the Company's Board of Directors.

3. Newly issued or revised standards and interpretations

(1) Changes in accounting policies resulting from applying for the first time certain standards and amendments

The Group applied for the first time International Financial Reporting Standards, International Accounting Standards, and Interpretations issued, revised or amended which are recognized by Financial Supervisory Commission ("FSC") and become effective for annual periods beginning on or after 1 January 2018. The nature and the impact of each new standard and amendment that has a material effect on the Group is described below:

(1) IFRS 15 "Revenue from Contracts with Customers" (including Amendments to IFRS 15 "Clarifications to IFRS 15 Revenue from Contracts with Customers")

IFRS 15 replaces IAS 11 Construction Contracts, IAS 18 Revenue and related Interpretations. In accordance with the transition provision in IFRS 15, the Group elected

to recognize the cumulative effect of initially applying IFRS 15 at the date of initial application (January 1, 2018). The Group also elected to apply this standard retrospectively only to contracts that are not completed contracts at the date of initial application.

The Group's principal activities consist of the sale of goods and processing services. The impacts arising from the adoption of IFRS 15 on the Group are summarized as follows:

A. Please refer to Note 4 for the accounting policies before or after 1 January 2018.

B. Sale of goods

Before 1 January 2018, revenue from sale of goods was recognized when goods have been delivered to the buyer. Starting from 1 January 2018, in accordance with IFRS 15, the Group recognized revenue when (or as) the Group satisfies a performance obligation by transferring a promised good to a customer. IFRS 15 has no impact on the Group's revenue recognition from sale of goods. However, for some contracts, part of the consideration was received from customers upon signing the contract, then the Group has the obligation to provide the services subsequently. Before 1 January 2018, the Group recognized the consideration received in advance from customers under other current liabilities. Starting from 1 January 2018, in accordance with IFRS 15, it should be recognized as contract liabilities. The amount reclassified from other current liabilities to contracts liabilities of the Group as at the date of initial application was NT\$83,085. In addition, compared with the requirements of IAS 18, other current liabilities decreased by NT\$78,502 thousand and the contract liabilities increased by NT\$78,502 thousand as of March 31, 2018.

C. The considerations paid to customers

The accounting treatment the considerations paid to customers under IAS 18 was to record it under the caption of operating expense while, in accordance with IFRS 15, the Group shall record it as a reduction against revenue. Though, there were no impacts on the assets, liabilities or equity as of the adoption date.

Besides, in comparison with the requirement of IAS 18, operating revenues under IFRS 15 for the three-month period ended March 31, 2018 decreased by NT\$192,098 thousand and selling and marketing expenses decreased by NT\$192,098 thousand.

Grape King Bio Ltd. and Subsidiaries

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(REVIEWED BUT UNAUDITED)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

In accordance with the transitional provisions of IFRS 15, the Group elects to recognize the cumulative effect of initially applying IFRS15 at the date of initial application (1 January 2018). If the Group had recorded the considerations paid to customers as a reduction against revenue in accordance with IFRS 15 for the three-month period ended March 31, 2017, the impact on the income statement accounts then would have been as follows.

account	For the three-month period ended March 31, 2018 (Adopting IFRS 15)		For the three-month period ended March 31, 2017 (If adopting IFRS 15)		For the three-month period ended March 31, 2017 (Adopting IAS 18)	
	Amount	%	Amount	%	Amount	%
Comprehensive Income:						
Operating revenues	\$1,932,426	100.00	\$1,808,198	100.00	\$2,003,929	100.00
Operating costs	(392,162)	(20.29)	(264,573)	(14.63)	(264,573)	(13.20)
Gross profit	1,540,264	79.71	1,543,625	85.37	1,739,356	86.80
Operating expenses :						
Selling and marketing	(940,111)	(48.65)	(962,836)	(53.25)	(1,158,567)	(57.82)
General and administrative	(99,257)	(5.14)	(97,376)	(5.38)	(97,376)	(4.86)
Research and development	(41,111)	(2.13)	(36,345)	(2.01)	(36,345)	(1.81)
Operating expenses total	(1,080,479)	(55.92)	(1,096,557)	(60.64)	(1,292,288)	(64.49)
Operating income	459,785	23.79	447,068	24.73	447,068	22.31
Non-operating income and expenses	14,737	0.77	14,446	0.79	14,446	0.72
Income before income tax	474,522	24.56	461,514	25.52	461,514	23.03
Income tax expense	(98,734)	(5.11)	(80,004)	(4.42)	(80,004)	(3.99)
Net income	375,788	19.45	381,510	21.10	381,510	19.04
Total other comprehensive income, net of tax	9,361	0.48	(23,927)	(1.32)	(23,927)	(1.20)
Total comprehensive income	\$385,149	19.93	\$357,583	19.78	\$357,583	17.84
Net income attributable to:						
Stockholders of the parent	\$260,313	13.47	\$258,825	14.31	\$258,825	12.92
Non-controlling interests	115,475	5.98	122,685	6.79	122,685	6.12
	\$375,788	19.45	\$381,510	21.10	\$381,510	19.04
Total comprehensive income attributable to:						
Stockholders of the parent	\$269,674	13.95	\$234,898	12.99	\$234,898	11.72
Non-controlling interests	115,475	5.98	122,685	6.79	122,685	6.12

Grape King Bio Ltd. and Subsidiaries

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(REVIEWED BUT UNAUDITED)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

	\$385,149	19.93	\$357,583	19.78	\$357,583	17.84
Earnings per share(NTD)						
Earnings per share-basic (In NT\$)	1.93		1.92		1.92	
Earnings per share-diluted (In NT\$)	1.92		1.90		1.90	

D. Please refer to Note 4, Note 5 and Note 6 for additional disclosure note required by IFRS 15.

(2) IFRS 9“Financial Instruments”

IFRS 9 replaces IAS 39 Financial Instruments: Recognition and Measurement. In accordance with the transition provision in IFRS 9, the Group elected not to restate prior periods at the date of initial application (1 January 2018). The adoption of IFRS 9 has the following impacts on the Group:

- A. The Group adopted IFRS 9 since 1 January 2018 and it adopted IAS 39 before 1 January 2018. Please refer to Note 4 for more details on accounting policies.
- B. In accordance with the transition provision in IFRS 9, the assessment of the business model and classification of financial assets into the appropriate categories are based on the facts and circumstances that existed as at 1 January 2018. The classifications of financial assets and it carrying amounts as at 1 January 2018 are as follow:

IAS 39	Carrying amounts	IFRS 9	Carrying amounts
Measurement categories		Measurement categories	
Fair value through profit or loss	\$70,376	Fair value through profit or loss	\$70,376
Available-for-sale financial assets (including NT\$28,028 thousand measured at cost)	28,028	Equity instruments measured at fair value through other comprehensive income	18,387

Grape King Bio Ltd. and Subsidiaries

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(REVIEWED BUT UNAUDITED)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

At amortized cost	2,271,512	At amortized cost (including	2,271,512
Loans and receivables (including cash and cash equivalents, notes receivables, trade receivables, debt instrument investments for which no active market exists and other receivables)		cash and cash equivalents, notes receivables, trade receivables, financial assets measured at amortized cost and other receivables)	
Total	<u>\$2,369,916</u>	Total	<u>\$2,360,275</u>

C. The transition from IAS 39 to IFRS 9 as at 1 January 2018, the changes in the classifications of financial assets and financial liabilities are as follow:

IAS 39	Carrying amounts	IFRS 9	Class of financial instruments	Carrying amounts	Difference	Retained earnings	Other components of equity
						Adjusted amounts	Adjusted amounts
Financial assets at fair value through profit or loss (Note 1)	\$70,376	Measured at fair value through profit or loss (Note 1)		\$70,376	\$-	\$-	\$-
Available-for-sale financial assets (including initial investment cost of NT\$28,028 thousand and show separately as investments measured at cost) (Note 2)	28,028	Equity instruments measured at fair value through other comprehensive income		18,387	(9,641)	-	(9,641)
Loans and receivables (Note 3)							
Cash and cash equivalents	1,920,497	Cash and cash equivalents		1,920,497	-	-	-
Debt instrument investments for which no active market exists (noncurrent included)	184,535	Financial assets measured at amortized costs (noncurrent included)		184,535	-	-	-
Notes receivables	5,753	Notes receivables		5,753	-	-	-
Trade receivables (related parties included)	154,616	Trade receivables (include related parties)		154,616	-	-	-
Other receivables	6,111	Other receivables		6,111	-	-	-

Grape King Bio Ltd. and Subsidiaries

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(REVIEWED BUT UNAUDITED)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

Subtotal	2,271,512 Subtotal	2,271,512	-	-	-
Total	<u>\$2,369,916 Total</u>	<u>\$2,360,275</u>	<u>\$(9,641)</u>	<u>\$-</u>	<u>\$(9,641)</u>

Note 1: In accordance with IAS 39, financial assets classified as held for trading which measured at fair value through profit or loss are included investments in funds and stocks of listed companies. In accordance with IFRS 9, as the cash flow characteristics for funds are not solely payments of principal and interest on the principal amount outstanding, so they are classified as financial assets mandatorily measured at fair value through profit or loss.

Note 2: In accordance with of IAS 39, available-for-sale financial assets are stocks of unlisted companies. Details are described as follow:

Stocks (unlisted companies)

The assessment is based on facts and circumstances that existed as of January 1, 2018. As the equity investments are not held-for-trading, the Group elects to designate them as financial assets measured at fair value through other comprehensive income. As of January 1, 2018, the Group reclassified available-for-sale financial assets (including measured at cost) to financial assets measured at fair value through other comprehensive income of NT\$18,387 thousand.

Related adjustments are described as follow:

The stocks of unlisted companies previously measured at cost in accordance with IAS 39 had an original cost NT\$28,028 thousand and was fully impaired. However, in accordance with IFRS 9, stocks of unlisted companies must be measured at fair value. The fair value of the stocks of unlisted companies was NT\$18,387 thousand as at 1 January 2018. The Group adjusted the carrying amount of financial assets measured at fair value through other comprehensive income of NT\$18,387 thousand and also adjusted the other equity by NT\$9,641 thousand, respectively.

Note 3: In accordance with IAS 39, the cash flow characteristics for loans and receivables are solely payments of principal and interest on the principal amount outstanding. The assessment of the business model is based on the facts and circumstances that existed as at 1 January 2018. These financial assets were measured at amortized cost as they were held within a business model whose objective was to hold financial assets in order to collect contractual cash flows. Besides, in accordance with IFRS 9, there was no adjustment arised from the assessment of impairment losses for the aforementioned assets as at 1 January 2018. Therefore, there is no impact on the carrying amount as at 1 January 2018.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(REVIEWED BUT UNAUDITED)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

As of January 1, 2018, debt instrument investments for which no active market exists (noncurrent included) of NT\$184,535 thousand were reclassified to financial assets measured at amortized cost.

D. Please refer to Note 4, Note 5, Note 6 and Note 12 for the related disclosures required by IFRS 7 and IFRS 9.

(2) Standards or interpretations issued, revised or amended, by International Accounting Standards Board (“IASB”) which are endorsed by FSC, but not yet adopted by the Group as at the end of the reporting period are listed below.

None

(3) Standards or interpretations issued, revised or amended, by IASB but not yet endorsed by FSC at the date of issuance of the Group’s financial statements are listed below.

Items	New, Revised or Amended Standards and Interpretations	Effective Date issued by IASB
a	IFRS 10 “Consolidated Financial Statements” and IAS 28 “Investments in Associates and Joint Ventures” — Sale or Contribution of Assets between an Investor and its Associate or Joint Ventures	To be determined by IASB
b	IFRS 16 “Leases”	January 1, 2019
c	IFRIC 23 “Uncertainty Over Income Tax Treatments”	January 1, 2019
d	IFRS 17 “Insurance Contracts”	January 1, 2021
e	IAS 28 “Investment in Associates and Joint Ventures” — Amendments to IAS 28	January 1, 2019
f	Prepayment Features with Negative Compensation (Amendments to IFRS 9)	January 1, 2019
g	Improvements to International Financial Reporting Standards (2015-2017 cycle)	January 1, 2019
h	Plan Amendment, Curtailment or Settlement (Amendments to IAS 19)	January 1, 2019

(a) IFRS 10 “Consolidated Financial Statements” and IAS 28 “Investments in Associates and Joint Ventures” — Sale or Contribution of Assets between an Investor and its Associate or Joint Ventures

Grape King Bio Ltd. and Subsidiaries

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(REVIEWED BUT UNAUDITED)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

The amendments address the inconsistency between the requirements in IFRS 10 Consolidated Financial Statements and IAS 28 Investments in Associates and Joint Ventures, in dealing with the loss of control of a subsidiary that is contributed to an associate or a joint venture. IAS 28 restricts gains and losses arising from contributions of non-monetary assets to an associate or a joint venture to the extent of the interest attributable to the other equity holders in the associate or joint ventures. IFRS 10 requires full profit or loss recognition on the loss of control of the subsidiary. IAS 28 was amended so that the gain or loss resulting from the sale or contribution of assets that constitute a business as defined in IFRS 3 between an investor and its associate or joint venture is recognized in full. IFRS 10 was also amended so that the gains or loss resulting from the sale or contribution of a subsidiary that does not constitute a business as defined in IFRS 3 between an investor and its associate or joint venture is recognized only to the extent of the unrelated investors' interests in the associate or joint venture. The effective date of the amendments has been postponed indefinitely, but early adoption is allowed.

(b) IFRS 16 "Leases"

The new standard requires lessees to account for all leases under a single on-balance sheet model (subject to certain exemptions). Lessor accounting still uses the dual classification approach: operating lease and finance lease.

(c) IFRIC 23 "Uncertainty Over Income Tax Treatments"

The Interpretation clarifies application of recognition and measurement requirements in IAS 12 "Income Taxes" when there is uncertainty over income tax treatments.

(d) IFRS 17 "Insurance Contracts"

IFRS 17 provides a comprehensive model for insurance contracts, covering all relevant accounting aspects (including recognition, measurement, presentation and disclosure requirements). The core of IFRS 17 is the General (building block) Model, under this model, on initial recognition, an entity shall measure a group of insurance contracts at the total of the fulfilment cash flows and the contractual service margin. The fulfilment cash flows comprise of the following:

Grape King Bio Ltd. and Subsidiaries

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(REVIEWED BUT UNAUDITED)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

- (i) Estimates of future cash flows;
- (ii) Discount rate: an adjustment to reflect the time value of money and the financial risks related to the future cash flows, to the extent that the financial risks are not included in the estimates of the future cash flows; and
- (iii) A risk adjustment for non-financial risk.

The carrying amount of a group of insurance contracts at the end of each reporting period shall be the sum of the liability for remaining coverage and the liability for incurred claims. Other than the General Model, the standard also provides a specific adaptation for contracts with direct participation features (the Variable Fee Approach) and a simplified approach (Premium Allocation Approach) mainly for short-duration contracts.

- (e) IAS 28“Investment in Associates and Joint Ventures” — Amendments to IAS 28

The amendments clarify that an entity applies IFRS 9 to long-term interests in an associate or joint venture that form part of the net investment in the associate or joint venture before it applies IAS 28, and in applying IFRS 9, does not take account of any adjustments that arise from applying IAS 28.

- (f) Prepayment Features with Negative Compensation (Amendments to IFRS 9)

The amendment allows financial assets with prepayment features that permit or require a party to a contract either to pay or receive reasonable compensation for the early termination of the contract, to be measured at amortized cost or at fair value through other comprehensive income.

- (g) Improvements to International Financial Reporting Standards (2015-2017 cycle):

IFRS 3 “Business Combinations”

The amendments clarify that an entity that has joint control of a joint operation shall remeasure its previously held interest in a joint operation when it obtains control of the business.

Grape King Bio Ltd. and Subsidiaries

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(REVIEWED BUT UNAUDITED)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

IFRS 11 “Joint Arrangements”

The amendments clarify that an entity that participates in, but does not have joint control of, a joint operation does not remeasure its previously held interest in a joint operation when it obtains joint control of the business.

IAS 12 “Income Taxes”

The amendments clarify that an entity shall recognize the income tax consequences of dividends in profit or loss, other comprehensive income or equity according to where the entity originally recognized those past transactions or events.

IAS 23 “Borrowing Costs”

The amendments clarify that an entity should treat as part of general borrowings any borrowing made specifically to obtain an asset when the asset is ready for its intended use or sale.

(h) Plan Amendment, Curtailment or Settlement (Amendments to IAS 19)

The amendments clarify that when a change in a defined benefit plan is made (such as amendment, curtailment or settlement, etc.), the entity should use the updated assumptions to remeasure its net defined benefit liability or asset.

The abovementioned standards and interpretations issued by IASB have not yet endorsed by FSC at the date when the Group’s financial statements were authorized for issue, the local effective dates are to be determined by FSC. As the Group is still currently determining the potential impact of the standards and interpretations listed under (2), it is not practicable to estimate their impact on the Group at this point in time. All other standards and interpretations have no material impact on the Group.

4. Summary of significant accounting policies

(1) Statement of compliance

The consolidated financial statements of the Group for the three-month ended March 31, 2018 and 2017 have been prepared in accordance with the Regulations Governing the Preparation

Grape King Bio Ltd. and Subsidiaries

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(REVIEWED BUT UNAUDITED)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

of Financial Reports by Securities Issuers (“the Regulations”) and IAS 34 Interim Financial Reporting as endorsed and become effective by the FSC.

Except the following 4(4) ~ 4(8), the accounting policies applied in these consolidated financial statements are consistent with those applied in the consolidated financial statements for the year ended December 31, 2017. For more details, please refer to Note 4 of the Company’s consolidated financial statements for the year ended December 31, 2017.

(2) Basis of preparation

The consolidated financial statements have been prepared on a historical cost basis, except for financial instruments that have been measured at fair value. The consolidated financial statements are expressed in thousands of New Taiwan Dollars (“NT\$”) unless otherwise stated.

(3) Basis of consolidation

The same principles of consolidation have been applied in the Company’s consolidated financial statements as those applied in the Company’s consolidated financial statements for the year ended December 31, 2017. For the principles of consolidation, please refer to Note 4(3) of the Company’s consolidated financial statements for the year ended December 31, 2017.

The consolidated entities are listed as follows:

Investor	Subsidiary	Main businesses	Percentage of ownership (%)		
			As of		
			Mar. 31, 2018	Dec. 31, 2017	Mar. 31, 2017
The Company	Pro-partner Inc. (Pro-partner) (NOTE 2)	Sales	60%	60%	60%
The Company	GRAPE KING INTERNATIONAL INVESTMENT INC. (BVI) (GKBVI)	Investment	100%	100%	100%
The Company	Rivershine Ltd. (Rivershine)	Sales	100%	100%	100%

Grape King Bio Ltd. and Subsidiaries

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(REVIEWED BUT UNAUDITED)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

GKBVI	Shanghai Grape King Enterprise Co., Ltd. (Shanghai Grape King)	Manufacturing and Sales	100%	100%	100%
GKBVI	Shanghai Rivershine Ltd. (Shanghai Rivershine)	Sales	100% (NOTE 1)	100% (NOTE 1)	-

Note 1: Shanghai Rivershine Ltd. was established in June 2017 as a wholly-owned subsidiary of GKBVI.

Note2: The financial statements of Pro-partner Inc. are based solely on the reports of the other auditors. As of March 31, 2018 and 2017, total assets of Pro-partner Inc. were NT\$5,159,705 thousand and NT\$5,217,397 thousand, and the operating revenues for the three-month periods then ended were NT\$1,584,326 thousand and NT\$1,841,981 thousand.

(4) Foreign currency transactions

The Group's consolidated financial statements are presented in New Taiwan Dollar, which is the parent company's functional currency. Each entity in the Group determines its own functional currency and items included in the financial statements of each entity are measured using that functional currency.

Transactions in foreign currencies are initially recorded by the Group entities at their respective functional currency rates prevailing at the date of the transaction. At the reporting date, monetary items denominated in foreign currencies are retranslated at the prevailing functional currency closing rate of exchange; non-monetary items measured at fair value in a foreign currency are retranslated using the exchange rates at the date when the fair value is determined; and non-monetary items measured at historical cost in a foreign currency are translated using the exchange rates as at the dates of the initial transactions.

All exchange differences arising on the settlement monetary items or on translating are taken to profit or loss in the period in which they arise except for the following:

- A. Exchange differences arising from foreign currency borrowings for an acquisition of a qualifying asset to the extent that they are regarded as an adjustment to interest costs are included in the borrowing costs that are eligible for capitalization.

Grape King Bio Ltd. and Subsidiaries

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(REVIEWED BUT UNAUDITED)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

- B. Foreign currency items within the scope of IFRS 9 Financial Instruments (Before 1 January 2018: IAS 39 Financial Instruments: Recognition and Measurement) are accounted for based on the accounting policy for financial instruments.
- C. Exchange differences arising on a monetary item that forms part of a reporting entity's net investment in a foreign operation is recognized initially in other comprehensive income and reclassified from equity to profit or loss on disposal of the net investment.

When a gain or loss on a non-monetary item is recognized in other comprehensive income, any exchange component of that gain or loss is recognized in other comprehensive income. When a gain or loss on a non-monetary item is recognized in profit or loss, any exchange component of that gain or loss is recognized in profit or loss.

(5) Financial instruments

Financial assets and financial liabilities are recognized when the Group becomes a party to the contractual provisions of the instrument.

Financial assets and financial liabilities within the scope of IFRS 9 Financial Instruments (Before 1 January 2018: IAS 39 Financial Instruments: Recognition and Measurement) are recognized initially at fair value plus or minus, in the case of investments not at fair value through profit or loss, directly attributable transaction costs.

A. Financial instruments: Recognition and Measurement

The accounting policy from 1 January 2018 as follow:

The Group accounts for regular way purchase or sales of financial assets on the trade date.

The Group classified financial assets as subsequently measured at amortized cost, fair value through other comprehensive income or fair value through profit or loss on the basis of both:

- (a) the Group's business model for managing the financial assets and
- (b) the contractual cash flow characteristics of the financial asset.

Financial assets measured at amortized cost

A financial asset is measured at amortized cost if both of the following conditions are met and presented as note receivables, trade receivables financial assets measured at amortized cost and other receivables etc., on balance sheet as at the reporting date:

- (a) the financial asset is held within a business model whose objective is to hold financial assets in order to collect contractual cash flows and
- (b) the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

Such financial assets are subsequently measured at amortized cost (the amount at which the financial asset is measured at initial recognition minus the principal repayments, plus or minus the cumulative amortization using the effective interest method of any difference between the initial amount and the maturity amount and adjusted for any loss allowance) and is not part of a hedging relationship. A gain or loss is recognized in profit or loss when the financial asset is derecognized, through the amortization process or in order to recognize the impairment gains or losses.

Interest revenue is calculated by using the effective interest method. This is calculated by applying the effective interest rate to the gross carrying amount of a financial asset except for:

- (a) purchased or originated credit-impaired financial assets. For those financial assets, the Group applies the credit-adjusted effective interest rate to the amortized cost of the financial asset from initial recognition.
- (b) financial assets that are not purchased or originated credit-impaired financial assets but subsequently have become credit-impaired financial assets. For those financial assets, the Group applies the effective interest rate to the amortized cost of the financial asset in subsequent reporting periods.

Financial asset measured at fair value through other comprehensive income

A financial asset is measured at fair value through other comprehensive income if both of the following conditions are met:

- (a) the financial asset is held within a business model whose objective is achieved by both collecting contractual cash flows and selling financial assets and
- (b) the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

Besides, at initial recognition, the Group make an irrevocable election to present in other comprehensive income subsequent changes in the fair value of an investment in an equity instrument within the scope of IFRS 9 that is neither held for trading nor contingent consideration recognized by an acquirer in a business combination to which IFRS 3 applies. Amounts presented in other comprehensive income are not be subsequently transferred to profit or loss (when disposal of such equity instrument, its cumulated amount included in other components of equity is transferred directly to the retained earnings) and should recorded as financial assets measured at fair value through other comprehensive income on balance sheet. Dividends on such investment are recognized in profit or loss unless the dividends clearly represents a recovery of part of the cost of investment.

Financial asset measured at fair value through profit or loss

Financial assets were measured at amortized cost or measured at fair value through other comprehensive income only if they met particular conditions. All other financial assets were measured at fair value through profit or loss and presented on the balance sheet as financial assets measured at fair value through profit or loss.

Such financial assets are measured at fair value, the gains or losses resulting from remeasurement is recognized in profit or loss which includes any dividend or interest received on such financial assets.

The accounting policy before 1 January 2018 as follow:

The Group accounts for regular way purchase or sales of financial assets on the trade date.

Financial assets of the Group are classified as financial assets at fair value through profit or loss, held-to-maturity investments, available-for-sale financial assets, and loans and receivables. The Group determines the classification of its financial assets at initial recognition.

Financial assets at fair value through profit or loss

Financial assets at fair value through profit or loss include financial assets held for trading and financial assets designated as at fair value through profit or loss.

A financial asset is classified as held for trading if:

- (a) it is acquired principally for the purpose of selling in short term;
- (b) on initial recognition it is part of a portfolio of identified financial instruments that are managed together and for which there is evidence of a recent actual pattern of short-term profit-taking; or
- (c) it is a derivative (except for a derivative that is a financial guarantee contract or a designated and effective hedging instrument).

If a contract contains one or more embedded derivatives, the entire hybrid (combined) contract may be designated as a financial asset at fair value through profit or loss; or a financial asset may be designated as at fair value through profit or loss when doing so results in more relevant information, because either:

- A. it eliminates or significantly reduces a measurement or recognition inconsistency; or
- B. a group of financial assets, financial liabilities or both is managed and its performance is evaluated on a fair value basis, in accordance with a documented risk management or investment strategy, and information about the group is provided internally on that basis to the key management personnel.

Financial assets at fair value through profit or loss are measured at fair value with changes in fair value recognized in profit or loss. Dividends or interests on financial assets at fair value through profit or loss are recognized in profit or loss (including those received during the period of initial investment).

Grape King Bio Ltd. and Subsidiaries

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(REVIEWED BUT UNAUDITED)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

If financial assets do not have quoted prices in an active market and their fair value cannot be reliably measured, then they are classified as financial assets measured at cost on balance sheet and carried at cost net of accumulated impairment losses, if any, as at the reporting date.

Available-for-sale financial assets

Available-for-sale financial assets are non-derivative financial assets that are designated as available-for-sale or those not classified as financial assets at fair value through profit or loss, held-to-maturity investments, or loans and receivables.

Foreign exchange gains and losses and interest calculated using the effective interest method relating to monetary available-for-sale financial assets, or dividends on an available-for-sale equity instrument, are recognized in profit or loss. Subsequent measurement of available-for-sale financial assets at fair value is recognized in equity until the investment is derecognized, at which time the cumulative gain or loss is reclassified to profit or loss.

If equity instrument investments do not have quoted prices in an active market and their fair value cannot be reliably measured, then they are classified as financial assets measured at cost on balance sheet and carried at cost net of accumulated impairment losses, if any, as at the reporting date.

Loans and receivables

Loans and receivables are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market other than those that the Group upon initial recognition designates as available for sale, or those for which the holder may not recover substantially all of its initial investment.

Loans and receivables are separately presented on the balance sheet as receivables or debt instrument investments for which no active market exists. After initial measurement, such financial assets are subsequently measured at amortized cost using the effective interest rate method, less impairment. Amortized cost is calculated by taking into account any discount or premium on acquisition and fee or transaction costs. The effective interest method amortization is recognized in profit or loss.

Grape King Bio Ltd. and Subsidiaries

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(REVIEWED BUT UNAUDITED)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

B. Impairment of financial assets

The accounting policy from 1 January 2018 as follow:

The Group is recognized a loss allowance for expected credit losses on debt instrument investments measured at fair value through other comprehensive income and financial asset measured at amortized cost. The loss allowance on debt instrument investments measured at fair value through other comprehensive income is recognized in other comprehensive income and not reduce the carrying amount in the statement of financial position.

The Group measures expected credit losses of a financial instrument in a way that reflects:

- (a) an unbiased and probability-weighted amount that is determined by evaluating a range of possible outcomes;
- (b) the time value of money; and
- (c) reasonable and supportable information that is available without undue cost or effort at the reporting date about past events, current conditions and forecasts of future economic conditions.

The loss allowance is measures as follow:

- A. At an amount equal to 12-month expected credit losses: the credit risk on a financial asset has not increased significantly since initial recognition or the financial asset is determined to have low credit risk at the reporting date. In addition, the Group measures the loss allowance for a financial asset at an amount equal to lifetime expected credit losses in the previous reporting period, but determines at the current reporting date that condition is no longer met.
- B. At an amount equal to the lifetime expected credit losses: the credit risk on a financial asset has increased significantly since initial recognition or financial asset that is purchased or originated credit-impaired financial asset.
- C. For trade receivables or contract assets arising from transactions within the scope of IFRS 15, the Group measures the loss allowance at an amount equal to lifetime expected credit losses.

Grape King Bio Ltd. and Subsidiaries

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(REVIEWED BUT UNAUDITED)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

At each reporting date, the Group needs to assess whether the credit risk on a financial asset has been increased significantly since initial recognition by comparing the risk of a default occurring at the reporting date and the risk of default occurring at initial recognition. Please refer to Note 12 for further details on credit risk.

The accounting policy before January 1, 2018 as follow:

The Group assesses at each reporting date whether there is any objective evidence that a financial asset other than the financial assets at fair value through profit or loss is impaired. A financial asset is deemed to be impaired if, and only if, there is objective evidence of impairment as a result of one or more loss events that has occurred after the initial recognition of the asset and that loss event has an impact on the estimated future cash flows of the financial asset. The carrying amount of the financial asset is impaired other than receivables impaired which are reduced through the use of an allowance account, is reduced directly and the amount of the loss is recognized in profit or loss.

A significant or prolonged decline in the fair value of an available-for-sale equity instrument below its cost is considered a loss event.

Other loss events include:

- (a) significant financial difficulty of the issuer or obligor; or
- (b) a breach of contract, such as a default or delinquency in interest or principal payments; or
- (c) it becoming probable that the borrower will enter bankruptcy or other financial reorganisation; or
- (d) the disappearance of an active market for that financial asset because of financial difficulties.

For held-to-maturity financial assets and loans and receivables measured at amortized cost, the Group first assesses individually whether objective evidence of impairment exists individually for financial asset that are individually significant, or collectively for financial assets that are not individually significant. If the Group determines that no objective evidence of impairment exists for an individually assessed financial asset, whether significant or not, it includes the asset in a group of financial assets with similar credit risk characteristics and collectively assesses them for impairment. If there is objective evidence that an impairment loss has been incurred, the amount of the loss is

measured as the difference between the assets carrying amount and the present value of estimated future cash flows. The present value of the estimated future cash flows is discounted at the financial assets original effective interest rate. If a loan has a variable interest rate, the discount rate for measuring any impairment loss is the current effective interest rate. Interest income is accrued based on the reduced carrying amount of the asset, using the rate of interest used to discount the future cash flows for the purpose of measuring the impairment loss.

Receivables together with the associated allowance are written off when there is no realistic prospect of future recovery. If, in a subsequent year, the amount of the estimated impairment loss increases or decreases because of an event occurring after the impairment was recognized, the previously recognized impairment loss is increased or reduced by adjusting the allowance account. If a write-off is later recovered, the recovery is credited to profit or loss.

In the case of equity investments classified as available-for-sale, where there is evidence of impairment, the cumulative loss – measured as the difference between the acquisition cost and the current fair value, less any impairment loss on that investment previously recognized in profit or loss – is removed from other comprehensive income and recognized in profit or loss. Impairment losses on equity investments are not reversed through profit or loss; increases in their fair value after impairment are recognized directly in other comprehensive income.

In the case of debt instruments classified as available-for-sale, the amount recorded for impairment is the cumulative loss measured as the difference between the amortized cost and the current fair value, less any impairment loss on that investment previously recognized in profit or loss. Future interest income continues to be accrued based on the reduced carrying amount of the asset, using the rate of interest used to discount the future cash flows for the purpose of measuring the impairment loss. The interest income is recognized in profit or loss. If, in a subsequent year, the fair value of a debt instrument increases and the increase can be objectively related to an event occurring after the impairment loss was recognized in profit or loss, the impairment loss is reversed through profit or loss.

C. Derecognition of financial assets

A financial asset is derecognized when:

- (a) The rights to receive cash flows from the asset have expired
- (b) The Group has transferred the asset and substantially all the risks and rewards of the asset have been transferred
- (c) The Group has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset.

On derecognition of financial assets in its entirety, the difference between the carrying amount and the consideration received or receivable including any cumulative gain or loss that had been recognized in other comprehensive income is recognized in earnings.

D. Financial liabilities and equity

Classification between liabilities or equity

The Group classifies the instrument issued as a financial liability or an equity instrument in accordance with the substance of the contractual arrangement and the definitions of a financial liability, and an equity instrument.

Equity instruments

An equity instrument is any contract that evidences a residual interest in the assets of an entity after deducting all of its liabilities. The transaction costs of an equity transaction are accounted for as a deduction from equity (net of any related income tax benefit) to the extent they are incremental costs directly attributable to the equity transaction that otherwise would have been avoided.

Compound instruments

The Group evaluates the terms of the convertible bonds issued to determine whether it contains both a liability and an equity component. Furthermore, the Group assesses if the economic characteristics and risks of the put and call options contained in the convertible bonds are closely related to the economic characteristics and risk of the host contract before separating the equity element.

For the liability component excluding the derivatives, its fair value is determined based on the rate of interest applied at that time by the market to instruments of comparable credit status. The liability component is classified as a financial liability measured at amortized cost before the instrument is converted or settled.

For the embedded derivative that is not closely related to the host contract (for example, if the exercise price of the embedded call or put option is not approximately equal on each exercise date to the amortized cost of the host debt instrument), it is classified as a liability component and subsequently measured at fair value through profit or loss unless it qualifies for an equity component. The equity component is assigned the residual amount after deducting from the fair value of the instrument as a whole the amount separately determined for the liability component. Its carrying amount is not remeasured in the subsequent accounting periods. If the convertible bond issued does not have an equity component, it is accounted for as a hybrid instrument in accordance with the requirements under IFRS 9 *Financial Instruments* (before January 1, 2018: IAS 39 *Financial Instruments: Recognition and Measurement*).

Transaction costs are apportioned between the liability and equity components of the convertible bond based on the allocation of proceeds to the liability and equity components when the instruments are initially recognized.

On conversion of a convertible bond before maturity, the carrying amount of the liability component being the amortized cost at the date of conversion is transferred to equity.

Financial liabilities

Financial liabilities within the scope of IFRS 9 *Financial Instruments* (before 1 January 2018: IAS 39 *Financial Instruments: Recognition and Measurement*) are classified as financial liabilities at fair value through profit or loss or financial liabilities measured at amortized cost upon initial recognition.

Financial liabilities at amortized cost

Financial liabilities measured at amortized cost include interest bearing loans and borrowings that are subsequently measured using the effective interest rate method after initial recognition. Gains or losses are recognized in profit or loss when the liabilities are derecognized as well as through the effective interest rate method amortization process.

Amortized cost is calculated by taking into account any discount or premium on acquisition and fees or transaction costs.

Derecognition of financial liabilities

A financial liability is derecognized when the obligation under the liability is discharged or cancelled or expires.

When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified (whether or not attributable to the financial difficulty of the debtor), such an exchange or modification is treated as a derecognition of the original liability and the recognition of a new liability, and the difference in the respective carrying amounts and the consideration paid, including any non-cash assets transferred or liabilities assumed, is recognized in profit or loss.

E. Offsetting of financial instruments

Financial assets and financial liabilities are offset and the net amount reported in the balance sheet if, and only if, there is a currently enforceable legal right to offset the recognized amounts and there is an intention to settle on a net basis, or to realize the assets and settle the liabilities simultaneously.

(6) Revenue recognition

The accounting policy from 1 January 2018 as follow:

The Group's revenue arising from contracts with customers are mainly include sale of goods and rendering of services. The accounting policies for the Group's types of revenue are explained as follow:

Sale of goods

The Group manufactures and sells of goods. Sales are recognized when control of the goods is transferred to the customer and the goods are delivered to the customers. Revenue is recognized based on the consideration stated in the contract. The remaining sales transactions are usually accompanied by volume discounts (based on the accumulated total sales amount

for a specified period). Therefore, revenue from these sales is recognized based on the price specified in the contract, net of the estimated volume discounts. Accumulated experience is used to estimate and provide for the discounts, using the expected value method. Revenue is only recognized to the extent that it is highly probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. During the period specified in the contract, refund liability is recognized for the products expected to be returned.

The credit period of the Group's sale of goods is from 30 to 135 days. For most of the contracts, when the Group transfers the goods to customers and has a right to an amount of consideration that is unconditional, these contracts are recognized as trade receivables. The period between the time when the Group transfers the goods to customers and when the customers pay for that goods is usually short and have no significant financing component to the contract. For a small part of the contracts, the Group has the right to transfer the goods to customers but does not has a right to an amount of consideration that is unconditional, these contacts should be presented as contract assets. Besides, in accordance with IFRS 9, the Group measures the loss allowance for a contract asset at an amount equal to the lifetime expected credit losses.

Rendering of services

Revenue from a service contract shall be recognized upon the performance obligations being met.

Revenue from technical services is recognized on an accrual basis in accordance with the substance of the relevant agreement provided that it is probable that the economic benefits will flow to the Company and the amount of revenue can be measured reliably.

The accounting policy before 1 January 2018 as follow:

Revenue is recognized to the extent that it is probable that the economic benefits will flow to the Group and the revenue can be reliably measured. Revenue is measured at the fair value of the consideration received or receivable. Conditions and methods for the recognition of various types of revenue are listed below:

Sale of goods

Revenue from the sale of goods is recognized when all the following conditions have been satisfied: significant risks and rewards of ownership of the goods have passed to the buyer; neither continuing managerial involvement nor effective control over the goods sold have been retained; the amount of revenue can be measured reliably; it is probable that the economic benefits associated with the transaction will flow to the entity; and the costs incurred in respect of the transaction can be measured reliably.

Rendering of services

Revenue from a service contract shall be recognized upon the performance obligations being met.

Revenue from technical services is recognized on an accrual basis in accordance with the substance of the relevant agreement provided that it is probable that the economic benefits will flow to the Company and the amount of revenue can be measured reliably.

Interest income

For all financial assets measured at amortized cost (including loans and receivables, interest income is recorded using the effective interest rate method and recognized in profit or loss.

Dividend income

Revenue is recognized when the Group's right to receive the payment is established.

(7) Post-employment benefits

Pension cost for an interim period is calculated on a year-to-date basis by using the actuarially determined pension cost rate at the end of the prior financial year, adjusted and disclosed for significant market fluctuations since that time and for significant curtailments, settlements, or other significant one-off events.

(8) Income taxes

Interim period income tax expense is accrued using the tax rate that would be applicable to expected total annual earnings, that is, the estimated average annual effective income tax rate applied to the pre-tax income of the interim period. Only current income tax expense is using the estimated average annual effective income tax rate while deferred income tax is recognized and measured in consistent with annual financial reporting in accordance with IAS 12, "Income Tax." The impact of tax rate change in interim period, if any, is recognized in earnings, other comprehensive income or directly equity.

5. Significant accounting judgements, estimates and assumptions

The preparation of the Group's consolidated financial statements require management to make judgments, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities, and the disclosure of contingent liabilities, at the end of the reporting period. However, uncertainty about these assumption and estimate could result in outcomes that require a material adjustment to the carrying amount of the asset or liability affected in future periods.

Except the following 5(1)~5(2), the significant accounting judgments, estimates and assumptions have been applied in the Company's consolidated financial statements for the three-month period ended March 31, 2018 are the same as those applied in the Company's consolidated financial statements for the year ended December 31, 2017. For significant accounting judgments, estimates and assumptions, please refer to Note 5 to the Company's consolidated financial statements for the year ended December 31, 2017.

1. Revenue recognition – sales returns and allowance

Starting from 1 January 2018:

The Group estimates sales returns and allowance based on historical experience and other known factors at the time of sale, which reduces the operating revenue. In assessing the aforementioned sales returns and allowance, on the basis of highly probable that a significant reversal in the amount of cumulative revenue recognized will not occur. Please refer to Note 6 for more details.

Before 1 January 2018:

The Group estimates sales returns and allowance based on historical experience and other known factors at the time of sale, which reduces the operating revenue. Please refer to Note 6 for more details.

2. Accounts receivables – estimation of impairment loss

Starting from 1 January 2018:

The Group estimates the impairment loss of accounts receivables at an amount equal to lifetime expected credit losses. The credit loss is the present value of the difference between the contractual cash flows that are due under the contract (carrying amount) and the cash flows that expects to receive (evaluate forward looking information). However, as the impact from the discounting of short-term receivables is not material, the credit loss is measured by the undiscounted cash flows. Where the actual future cash flows are lower than expected, a material impairment loss may arise. Please refer to Note 6 for more details.

Before 1 January 2018:

The Group considers the estimation of future cash flows when there is objective evidence showed indications of impairment. The amount of the loss is measured as the difference between the asset's carrying amount and the present value of estimated future cash flows (excluding future credit losses that have not been incurred) discounted at the financial asset's original effective interest rate. However, as the impact from the discounting of short-term receivables is not material, the impairment of short-term receivables is measured as the difference between the asset's carrying amount and the estimated undiscounted future cash flows. Where the actual future cash flows are lower than expected, a material impairment loss may arise. Please refer to Note 6 for more details.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(REVIEWED BUT UNAUDITED)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

6. Contents of significant accounts

(1) Cash and cash equivalents

	As of		
	Mar. 31, 2018	Dec. 31, 2017	Mar. 31, 2017
Cash on hand	\$4,945	\$3,546	\$4,362
Checkings and savings	1,126,674	1,138,371	1,003,968
Repurchase agreements collateralized by corporate bonds	399,642	249,790	529,546
Repurchase agreements collateralized by bonds	462,437	528,790	400,226
Total	<u>\$1,993,698</u>	<u>\$1,920,497</u>	<u>\$1,938,102</u>

(2) Financial assets at fair value through profit or loss

	As of		
	Mar. 31, 2018	Dec. 31, 2017	Mar. 31, 2017
		(note)	(note)
Mandatorily measured at fair value through profit or loss:			
Monetary fund	\$ 170,000		
Valuation adjustments	465		
Total	<u>\$ 170,465</u>		

	As of		
	Mar. 31, 2018	Dec. 31, 2017	Mar. 31, 2017
	(note)		
Financial assets held for trading:			
Monetary fund		\$70,000	\$240,000
Valuation adjustments		307	186
Subtotal		<u>70,307</u>	<u>240,186</u>
Embedded Derivatives:			
Right of redemption		69	139
Total		<u>\$70,376</u>	<u>\$240,325</u>

Grape King Bio Ltd. and Subsidiaries

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(REVIEWED BUT UNAUDITED)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

	As of		
	Mar. 31, 2018	Dec. 31, 2017	Mar. 31, 2017
Current	\$ 170,465	\$70,376	\$240,186
Non-current	-	-	139
Total	\$ 170,465	\$70,376	\$240,325

Note: The Group adopted IFRS 9 since 1 January 2018. The Group elected not to restate prior periods in accordance with the transition provision in IFRS 9.

Financial assets at fair value through profit or loss were not pledged.

(3) Financial assets at fair value through other comprehensive income

	As at		
	31 Mar. 2018	31 Dec. 2017 (note)	31 Mar. 2017 (note)
Equity instruments investments measured at fair value through other comprehensive income – Non-current:			
Unlisted companies stocks	\$16,664		

Note: The Group adopted IFRS 9 since 1 January 2018. The Group elected not to restate period periods in accordance with the transition provision in IFRS 9.

a. At 1 January 2016, the Company invested US\$917 thousand (equivalent to NT\$28,008 thousand) for 917,700 shares, representing 19% interest, of Fu-sheng International Inc. (Samoa). In 2016, the Company didn't participate an offering conducted by Fu-sheng International Inc. (Samoa) and its ownership interest in Fu-sheng International Inc. (Samoa) was reduced to 18.77%.

b. Financial assets at fair value through other comprehensive income were not pledged.

Grape King Bio Ltd. and Subsidiaries

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(REVIEWED BUT UNAUDITED)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

(4) Financial assets measured at cost

	As at		
	31 Mar. 2018	31 Dec. 2017	31 Mar. 2017
	(note)		
Unlisted companies stocks		\$28,028	\$28,028

	As at		
	31 Mar. 2018	31 Dec. 2017	31 Mar. 2017
	(note)		
Current		\$-	\$-
Non-current		28,028	28,028
Total		\$28,028	\$28,028

Note: The Group adopted IFRS 9 since 1 January 2018. The Group elected not to restate prior periods in accordance with the transition provision in IFRS 9.

The Group adopted IAS 39 before 1 January 2018. The above investments in the equity instruments of unlisted entities are measured at cost as the fair value of these investments are not reliably measurable due to the fact that the variability in the range of reasonable fair value measurements is significant for that investment and that the probabilities of the various estimates within the range cannot be reasonably assessed and used when measuring fair value.

Financial assets measured at cost were not pledged.

(5) Financial assets measured at amortized cost

	As at		
	31 Mar. 2018	31 Dec. 2017	31 Mar. 2017
		(note)	(note)
Time deposits	\$47,995		

Grape King Bio Ltd. and Subsidiaries

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(REVIEWED BUT UNAUDITED)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

	As at		
	31 Mar. 2018	31 Dec. 2017 (note)	31 Mar. 2017 (note)
Current	\$43,535		
Non-current	4,460		
Total	<u>\$47,995</u>		

Note: The Group adopted IFRS 9 since 1 January 2018. The Group elected not to restate prior periods in accordance with the transition provision in IFRS 9.

The Group classified certain financial assets as financial assets measured at amortized cost. Please refer to Note 8 for more details on financial assets measured at amortized cost under pledge and Note 12 for more details on credit risk management.

(6) Debt instrument investments for which no active market exists

	As at		
	31 Mar. 2018 (note)	31 Dec. 2017	31 Mar. 2017
Time deposit		<u>\$184,535</u>	<u>\$46,795</u>

	As at		
	31 Mar. 2018 (note)	31 Dec. 2017	31 Mar. 2017
Current		\$180,075	\$42,335
Non-current		4,460	4,460
Total		<u>\$184,535</u>	<u>\$46,795</u>

Note: The Group adopted IFRS 9 since 1 January 2018. The Group elected not to restate prior periods in accordance with the transition provision in IFRS 9.

The Group adopted IAS 39 before 1 January 2018 and classified certain financial assets as debt instrument investments for which no active market exists. Please refer to Note 8 for more details on debt instrument investments for which no active market exists under pledge.

Grape King Bio Ltd. and Subsidiaries

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(REVIEWED BUT UNAUDITED)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

(7) Notes receivables

	As of		
	Mar. 31, 2018	Dec. 31, 2017	Mar. 31, 2017
Notes receivables arising from operating activities	\$3,149	\$5,753	\$4,133
Less: loss allowance	-	-	-
Total	\$3,149	\$5,753	\$4,133

Notes receivables were not pledged.

The Group adopted IFRS 9 for impairment assessment since 1 January 2018. Please refer to Note 12 for more details on credit risk management.

(8) Trade receivables and Trade receivables—related parties

	As of		
	Mar. 31, 2018	Dec. 31, 2017	Mar. 31, 2017
Trade receivables	\$106,386	\$158,064	\$163,526
Less: loss allowance	(3,269)	(3,448)	(3,456)
Subtotal	103,117	154,616	160,070
Trade receivables from related parties	-	-	159
Less: loss allowance	-	-	-
Subtotal	-	-	159
Total	\$103,117	\$154,616	\$160,229

Accounts receivable which is expected to be outstanding for over one year have been recast for overdue receivable. Please refer to Note 6(10).

Trade receivables were not pledged.

Trade receivables are generally on the collection term of 30-135 days. The Group adopts IFRS 9 for impairment assessment since January 1, 2018 in considering the factors such as the counterparty and area to distinguish the different groups and to adopt the expected credit loss rate during the continuation period. The estimated loss ratio was small in the first quarter of 2018.

Grape King Bio Ltd. and Subsidiaries

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(REVIEWED BUT UNAUDITED)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

	Trade receivables
As of Jan. 1, 2018(in accordance with IAS 39)	\$3,448
Beginning adjusted retained earnings	-
As of Jan. 1, 2018(in accordance with IFRS 9)	3,448
Charge/(reversal) for the current period	(179)
Exchange differences	-
As of Mar. 31, 2018	<u>\$3,269</u>

The Group adopted IAS 39 for impairment assessment before 1 January 2018. The movements in the provision for impairment of trade receivables and trade receivables-related parties are as follows: (Please refer to Note 12 for more details on credit risk management.)

	Individually impaired	Collectively impaired	Total
As of Jan. 1, 2017	\$-	\$3,428	\$3,428
Charge/(reversal) for the current period	-	28	28
Exchange differences	-	-	-
As of Mar. 31, 2017	<u>\$-</u>	<u>\$3,456</u>	<u>\$3,456</u>

Aging analysis of trade receivables that are past due but not impaired was as follows:

As at	Neither past due nor impaired	Past due but not impaired:			Total
		<=90 days	90~180days	>180 days	
Mar. 31, 2018	\$96,605	\$6,361	\$74	\$77	\$103,117
Dec. 31, 2017	145,643	8,700	262	11	154,616
Mar. 31, 2017	141,046	19,163	9	11	160,229

(9)Inventories

	As of		
	Mar. 31, 2018	Dec. 31, 2017	Mar. 31, 2017
Raw materials	\$107,907	\$106,816	\$98,596
Supplies	25,449	28,614	31,640
Semi-finished goods and Work in process	152,910	158,357	142,960
Finished goods	152,143	193,936	179,002

Grape King Bio Ltd. and Subsidiaries

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(REVIEWED BUT UNAUDITED)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

Merchandise	4,470	4,335	25
Total	<u>\$442,879</u>	<u>\$492,058</u>	<u>\$452,223</u>

- a. The cost of inventories recognized in expenses in amount of NT\$392,162 thousand and NT\$264,573 thousand for the three-month periods ended March 31, 2018 and 2017, respectively, including the write-down of inventories, were detailed as following:

	For the three-month period ended March 31,	
	2018	2017
Inventory loss on retirement	\$3,174	\$1,482
Gains or loss from physical taking	(69)	(410)
Total	<u>\$3,105</u>	<u>\$1,072</u>

- b. No inventories were pledged.

(10) Prepayments and Other Assets

	As of		
	Mar. 31, 2018	Dec. 31, 2017	Mar. 31, 2017
Prepayment for purchase	\$10,365	\$23,000	\$19,508
Prepaid rental on land	46,405	46,023	45,696
Prepayment for equipment	445,877	307,293	144,146
Office Supplies	8,513	6,199	9,639
Other prepaid expenses	31,407	19,694	13,420
Other current assets	15,056	11,643	6,498
Refundable deposits	26,817	23,483	29,856
Overdue receivable	2,267	2,267	2,244
Less: loss allowance	(2,267)	(2,267)	(2,244)
Other noncurrent assets-other	22,742	22,752	19,960
Total	<u>\$607,182</u>	<u>\$460,087</u>	<u>\$288,723</u>
Current portion	\$65,341	\$60,535	\$49,065
Noncurrent portion	541,841	399,552	239,658
Total	<u>\$607,182</u>	<u>\$460,087</u>	<u>\$288,723</u>

Grape King Bio Ltd. and Subsidiaries

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(REVIEWED BUT UNAUDITED)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

- a. The amount recognized under the caption of “prepaid rental on land” is the land-transferring fees prepaid to the Ministry of Land and Resource of the People's Republic of China for acquiring the right to use the land in Shanghai Songjiang Industrial Zone. Shanghai Grape King rent the land for constructing the manufacturing plant from October 1997 to March 2044. All fees were paid in full when the lease agreement was entered into and have been amortized over the lease term.
- b. Overdue receivables were those expected not to be collected within a year and the Group has provided a full allowance for doubtful debts against them. And the Company holds collateral for other receivables of NT\$ 2,244 thousand.

(11) Property, plant and equipment

	Land		Building	Machinery	Vehicle	Leasehold	Other	Construction	Total
	Land	Improvement				improvement	facilities	in progress	
Cost:									
As of Jan. 1, 2018	\$3,055,915	\$1,974	\$3,167,264	\$1,167,117	\$12,973	\$34,635	\$344,919	\$311,633	\$8,096,430
Additions	-	-	13,008	4,378	(78)	-	9,816	83,216	110,340
Disposals	-	-	-	(170)	-	-	(65)	-	(235)
Transfers	-	-	-	44,114	-	-	-	(22,521)	21,593
Ex. Diff.	-	-	6,520	3,351	50	46	349	-	10,316
As of Mar. 31, 2018	\$3,055,915	\$1,974	\$3,186,792	\$1,218,790	\$12,945	\$34,681	\$355,019	\$372,328	\$8,238,444
As of Jan. 1, 2017									
As of Jan. 1, 2017	\$3,071,692	\$940	\$3,098,131	\$1,123,652	\$12,275	\$7,090	\$322,598	\$52,047	\$7,688,425
Additions	-	-	841	3,597	252	17,945	11,985	74,081	108,701
Disposals	-	-	(380)	(460)	-	-	(1,596)	-	(2,436)
Transfers	-	914	2,860	32,601	-	-	(19,109)	629	17,895
Ex. Diff.	-	-	(16,575)	(10,142)	(146)	(116)	(853)	-	(27,832)
As of Mar. 31, 2017	\$3,071,692	\$1,854	\$3,084,877	\$1,149,248	\$12,381	\$24,919	\$313,025	\$126,757	\$7,784,753
Accumulated									
Depreciation:									
As of Jan. 1, 2018	\$-	\$687	\$616,686	\$857,073	\$7,696	\$10,050	\$248,822	\$-	\$1,741,014
Depreciation	-	71	28,050	18,595	391	1,410	9,010	-	57,527
Disposals	-	-	-	(66)	-	-	(65)	-	(131)
Ex. Diff.	-	-	1,910	2,536	36	20	275	-	4,777
As of Mar. 31, 2018	\$-	\$758	\$646,646	\$878,138	\$8,123	\$11,480	\$258,042	\$-	\$1,803,187

Grape King Bio Ltd. and Subsidiaries

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(REVIEWED BUT UNAUDITED)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

As of 1 Jan. 2017	\$-	\$427	\$509,156	\$865,226	\$7,330	\$5,470	\$216,439	\$-	\$1,604,048
Depreciation	-	46	26,904	16,751	327	374	8,659	-	53,061
Disposals	-	-	(150)	(317)	-	-	(1,596)	-	(2,063)
Ex. Diff.	-	-	(4,530)	(9,093)	(127)	(49)	(716)	-	(14,515)
As of Mar. 31, 2017	\$-	\$473	\$531,380	\$872,567	\$7,530	\$ 5,795	\$222,786	\$-	\$1,640,531

Net carrying amount as of:

Mar. 31, 2018	\$3,055,915	\$1,216	\$2,540,146	\$340,652	\$4,822	\$23,201	\$96,977	\$372,328	\$6,435,257
Dec. 31, 2017	\$3,055,915	\$1,287	\$2,550,578	\$310,044	\$5,277	\$24,585	\$96,097	\$311,633	\$6,355,416
Mar. 31, 2017	\$3,071,692	\$1,381	\$2,553,497	\$276,681	\$4,851	\$19,124	\$90,239	\$126,757	\$6,144,222

- a. The significant part of the Company's building includes main plant, air conditioning, electrical and wastewater treatment equipment and decoration, and the related depreciation is calculated based on the estimated economic lives as below:

Significant part of buildings	Estimated economic lives
Main plant	30~60 years
Air conditioning and electrical	8~25 years
Wastewater treatment equipment	5~30 years
Decoration	15 years

- b. Please refer to Note 8 for details on property, plant and equipment under pledge.
- c. For the purpose of urban planning, Taoyuan City Government has expropriated the Company's partial land and land improvement in accordance with the Land Expropriation Act. The expropriation has been completed in 2017 and the Company was entitled to a compensation of NT\$109,274 thousand. The net amount of the compensation and the carrying amount in NT\$15,777 thousand of land and land improvement de-recognized was NT\$93,497 thousand, recorded under the caption of other incomes.

Grape King Bio Ltd. and Subsidiaries

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(REVIEWED BUT UNAUDITED)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

(12) Investment property

	Land	Building	Investment Properties under construction	Total	Accumulated depreciation	Net
As of Jan. 1, 2018						
As of Mar. 31, 2018	\$185,985	\$-	\$-	\$185,985	\$-	\$185,985
As of Jan. 1, 2017						
As of Mar. 31, 2017	\$185,985	\$-	\$-	\$185,985	\$-	\$185,985

(a) No investment property was pledged.

(b) The fair value of investment properties held by the Group as at March 31, 2018 and December 31, 2017, were similar. For more details on fair value measurements, please refer to Note 6(10) of the Company's consolidated financial statements for the year ended December 31, 2017.

(c) The investment property - land listed above includes a piece of agricultural land in amount of NT\$5,600 thousand, which has been acquired due to a settlement of doubtful accounts by the Company but registered under the name of the Company's chairman, Mr. Tseng. The Company has obtained a guaranteed note amounting NT\$5,600 thousand from Mr. Tseng for security purpose.

(13) Intangible assets

	Computer software	Trademark	Total
Cost:			
As of Jan. 1, 2018	\$19,042	\$15,049	\$34,091
Addition-acquired separately	81	-	81
As of Mar. 31, 2018	\$19,123	\$15,049	\$34,172
As of Jan. 1, 2017	\$16,627	\$15,049	\$31,676
Addition-acquired separately	152	-	152
As of Mar. 31, 2017	\$16,779	\$15,049	\$31,828

Grape King Bio Ltd. and Subsidiaries

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(REVIEWED BUT UNAUDITED)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

Accumulated Amortization:

As of Jan. 1, 2018	\$5,433	\$6,216	\$11,649
Amortization	761	981	1,742
As of Mar. 31, 2018	<u>\$6,194</u>	<u>\$7,197</u>	<u>\$13,391</u>

As of Jan. 1, 2017	\$2,751	\$2,290	\$5,041
Amortization	611	981	1,592
As of Mar. 31, 2017	<u>\$3,362</u>	<u>\$3,271</u>	<u>\$6,633</u>

Net carrying amount as of:

Mar. 31, 2018	<u>\$12,929</u>	<u>\$7,852</u>	<u>\$20,781</u>
Dec. 31, 2017	<u>\$13,609</u>	<u>\$8,833</u>	<u>\$22,442</u>
Mar. 31, 2017	<u>\$13,417</u>	<u>\$11,778</u>	<u>\$25,195</u>

Amortization expense of intangible assets under the statement of comprehensive income:

	<u>For three-month period ended</u>	
	<u>Mar. 31, 2018</u>	<u>Mar. 31, 2017</u>
Selling and marketing expenses	<u>\$31</u>	<u>\$-</u>
General administrative expenses	<u>\$1,711</u>	<u>\$1,592</u>

(14) Short-term borrowings

	Interest Rates (%)	As of		
		<u>Mar. 31, 2018</u>	<u>Dec. 31, 2017</u>	<u>Mar. 31, 2017</u>
Unsecured bank loans	0.98%~1.10%	<u>\$50,000</u>	<u>\$200,000</u>	<u>\$-</u>
Secured bank loans	0.99%~1.10%	<u>400,000</u>	<u>100,000</u>	<u>-</u>
		<u>\$450,000</u>	<u>\$300,000</u>	<u>\$-</u>

The Group's unused short-term lines of credits amount to NT\$1,800,000 thousand, NT\$1,750,000 thousand, and NT\$1,581,979 thousand, as of March 31, 2018, December 31, 2017, and March 31, 2017, respectively.

Please refer to Note 8 for property, plant and equipment pledged as collateral for short-term borrowings.

Grape King Bio Ltd. and Subsidiaries

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(REVIEWED BUT UNAUDITED)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

(15) Other Payables

	As of		
	Mar. 31, 2018	Dec. 31, 2017	Mar. 31, 2017
Bonus to direct sellers	\$653,354	\$858,166	\$654,140
Salaries and incentive bonus	168,463	125,426	121,041
Bonus to employees	246,072	254,218	277,752
Bonus to directors and supervisors	77,258	64,609	76,734
Other accrued expenses	106,834	112,857	89,973
Payables on equipment	49,650	125,378	90,649
Accrued VAT payable	28,266	65,895	28,675
Others	3,976	11,710	12,311
Total	<u>\$1,333,873</u>	<u>\$1,618,259</u>	<u>\$1,351,275</u>

(16) Other current liabilities

	As of		
	Mar. 31, 2018	Dec. 31, 2017	Mar. 31, 2017
Sales revenue received in advance	\$-	\$83,085	\$98,706
Unearned rent	5,305	5,256	4,766
Provisions for sales returns and allowances	(Note)	2,831	4,795
Refund liability	2,831	(Note)	(Note)
Other current liabilities-other	43,471	59,906	136,415
Total	<u>\$51,607</u>	<u>\$151,078</u>	<u>\$244,682</u>

Note: The Group accounts for the sales returns and allowances in accordance with IFRS 15 since 1 January 2018,

Provisions for sales returns and allowances

	Sales returns and allowances
As of January 1, 2017	\$7,500
Write off	(2,705)
As of March 31, 2017	<u>\$4,795</u>

Grape King Bio Ltd. and Subsidiaries

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(REVIEWED BUT UNAUDITED)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

	As of	
	Dec. 31, 2017	Mar. 31, 2017
Current	\$2,831	\$4,795
Non-current	-	-
Total	\$2,831	\$4,795

Sales returns and allowances

In December 2016, the Company was affected by news events suspected of being overdue goods. In order to resolve the consumers' concern, the Company have accepted the return from consumers by the end of February 2017 and recorded the estimated loss from sales return in amount of NT\$7,500 thousand in 2016. As of March 31, 2018, the actual sale return totaled to NT\$4,669 thousand.

(17) Bonds payable

	As of		
	Mar. 31, 2018	Dec. 31, 2017	Mar. 31, 2017
Domestic convertible bonds	\$113,355	\$171,207	\$169,794
Less: current portion	(113,355)	(171,207)	-
Net	\$-	\$-	\$169,794

a. Domestic convertible bonds payable

	As of		
	Mar. 31, 2018	Dec. 31, 2017	Mar. 31, 2017
Liability component:			
Principal amount	\$113,400	\$172,100	\$173,200
Interest Payable Refund from Bond Conversion	853	1,294	1,302
Premiums (discounts) on bonds payable	(898)	(2,187)	(4,708)
Subtotal	113,355	171,207	169,794
Less: current portion	(113,355)	(171,207)	-
Net	\$-	\$-	\$169,794

Grape King Bio Ltd. and Subsidiaries

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(REVIEWED BUT UNAUDITED)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

Embedded derivative—Redemption	\$-	\$69	\$139
Equity component—Convertible	\$5,134	\$7,792	\$7,842

For the details of gain or loss from valuation through P/L on embedded derivative—redemption right and the interest expense on the domestic convertible bonds payable, please refer to Note 6(25) to the consolidated financial statements.

- b. On August 26, 2015, the Company issued zero coupon unsecured convertible bonds. The terms of the convertible bonds were evaluated to include a liability component, embedded derivatives (a call option and a put option) and an equity component (an option for conversion into issuer's ordinary shares). The terms of the bonds are as follows:

(a) Issue amount: NT\$1,000,000 thousand.

(b) Period: From August 26, 2015 to August 26, 2018

(c) Secured or unsecured: Unsecured bonds

(d) Terms of Exchange:

① Underlying Securities: Common shares of the Company

② Exchange Period: The bonds are exchangeable at any time on or after September 27, 2015 and prior to August 26, 2018 into common shares of the Company except closed period.

③ Exchange Price and Adjustment: The exchange price was originally NT\$170.5 per share. The exchange price will be subject to adjustments upon the occurrence of certain events set out in the indenture.

Because the cash dividends - common stock, distributed on 2016, were higher than 1.5% of current per share, the conversion price should be adjusted in accordance with Unsecured convertible bonds and Terms of Exchange 11, The conversion price was adjusted to NT\$165.9 from July 24, 2016.

Because the cash dividends - common stock, distributed on 2017, were higher than 1.5% of current per share, the conversion price should be adjusted in accordance with

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(REVIEWED BUT UNAUDITED)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

Unsecured convertible bonds and Terms of Exchange 11, The conversion price was adjusted to NT\$160.6 from July 17, 2017.

- ④Redemption on the Maturity Date: The Company will redeem the bonds with interest refund (0.7519% of the principal amount) in cash if the convertible bonds will not have settled by the maturity date.

(e) Redemption clauses:

- ①The Company may redeem the bonds, in whole, but not in part, after a month of the issuance (September 27, 2015) and prior to the maturity date (July 17, 2018), at the principal amount of the bonds if the closing price of the Company's ordinary shares on the Taiwan Stock Exchange (TWSE) for a period of 30 consecutive trading days, is at least 30% of the conversion price.

- ②The Company may redeem the bonds, in whole, but not in part, at the Early Redemption Price if at least 90% in principal amount of the bonds has already been exchanged, redeemed or purchased and cancelled.

- c. There were NT\$886,600 thousand, NT\$827,900 thousand, and NT\$826,800 thousand bonds payable converted into shares as of March 31, 2018, December 31, 2017 and March 31, 2017, respectively.

(18) Long-term loan

Details of long-term loan as of March 31, 2018, December 31, 2017 and March 31, 2017 are as follows:

Lenders	As of Mar. 31, 2018	Interest Rate (%)	Maturity and terms
Secured Long-Term Loan from ChangHwa Commercial Bank	\$182,765	1.44%	Effective May 27, 2015 to May 27, 2030. Principal is repaid with interest payments due monthly.
Secured Long-Term Loan from Taiwan Cooperative Bank	359,838	1.44%	Effective May 27, 2015 to May 27, 2035. Principal is repaid with interest payments due monthly.
Subtotal	542,603		

Grape King Bio Ltd. and Subsidiaries

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(REVIEWED BUT UNAUDITED)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

Less: current portion	<u>(31,942)</u>
Total	<u><u>\$510,661</u></u>

Lenders	As of Dec. 31, 2017	Interest Rate (%)	Maturity and terms
Secured Long-Term Loan from ChangHwa Commercial Bank	\$186,195	1.44%	Effective May 27, 2015 to May 27, 2030. Principal is repaid with interest payments due monthly.
Secured Long-Term Loan from Taiwan Cooperative Bank	364,449	1.44%	Effective May 27, 2015 to May 27, 2035. Principal is repaid with interest payments due monthly.
Subtotal	<u>550,644</u>		
Less: current portion	<u>(31,974)</u>		
Total	<u><u>\$518,670</u></u>		

Lenders	As of Mar. 31, 2018	Interest Rate (%)	Maturity and terms
Secured Long-Term Loan from ChangHwa Commercial Bank	\$500,000	1.44%	Effective May 27, 2015 to May 27, 2030. Principal is repaid with interest payments due monthly.
Secured Long-Term Loan from Taiwan Cooperative Bank	480,831	1.44%	Effective May 27, 2015 to May 27, 2035. Principal is repaid with interest payments due monthly.
Subtotal	<u>980,831</u>		
Less: current portion	<u>(51,742)</u>		
Total	<u><u>\$929,089</u></u>		

Certain land and buildings were pledged as collaterals for secured bank loans. Please refer to Note 8 for details.

(19) Other noncurrent liabilities

	As of		
	Mar. 31, 2018	Dec. 31, 2017	Mar. 31, 2017
Other long-term payables	\$15,763	\$16,032	\$16,339
Accrued pension liabilities	2,624	3,540	6,343

Grape King Bio Ltd. and Subsidiaries

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(REVIEWED BUT UNAUDITED)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

Guarantee deposit received	23,855	23,382	20,666
Other noncurrent liabilities-other	53,972	54,560	57,154
Total	<u>\$96,214</u>	<u>\$97,514</u>	<u>\$100,502</u>

(20) Operating leases

Operating lease commitments – Group as lessor

Shanghai Grape King has entered into an operating lease agreement in a term from June 2014 to March 2034 with a non-related party. As of March 31, 2018, Shanghai Grape King has received prepaid rents, recorded under the caption of advances received, for the period of eight years. The movement schedule of prepaid rents is listed as follows:

	As of		
	Mar. 31, 2018	Dec. 31, 2017	Mar. 31, 2017
Beginning balance	\$57,720	\$63,855	\$63,855
Prepaid rent added in current period	-	10,832	2,328
Rent income recognized in current period	(1,206)	(16,039)	(4,053)
Exchange difference	1,027	(928)	(2,795)
Ending balance of prepaid rent	<u>\$57,541</u>	<u>\$57,720</u>	<u>\$59,335</u>

Advances received for operating leases are as follows:

	As of		
	Mar. 31, 2018	Dec. 31, 2017	Mar. 31, 2017
Other current liabilities	\$4,863	\$4,777	\$4,766
Other non-current liabilities-other	52,678	52,943	54,569
Total	<u>\$57,541</u>	<u>\$57,720</u>	<u>\$59,335</u>

Operating lease commitments – Group as lessee

Future minimum lease payments of non-cancellable operating leases are as following:

	As of		
	Mar. 31,2018	Dec. 31, 2017	Mar. 31,2017
Within one year	\$42,354	\$44,551	\$46,381
From one year to five years	72,250	80,303	96,219
Total	<u>\$114,604</u>	<u>\$124,854</u>	<u>\$142,600</u>

The lease contracts listed above were rental expenses for land from Science-based Park, operations centers, automobiles and warehouses.

Operating lease expenses recognized are as follows:

	For three-month period ended March 31,	
	2018	2017
Minimum lease payments	<u>\$15,646</u>	<u>\$14,580</u>

(21)Post-employment benefits

Defined contribution plan

Expenses under the defined contribution plan for the three-month periods ended March 31, 2018 and 2017 were NT\$6,709 thousand and NT\$5,213 thousand, respectively.

Defined benefit plan

Expenses under the defined benefit plan for the three-month periods ended March 31, 2018 and 2017 were NT\$152 thousand and NT\$208 thousand, respectively.

Grape King Bio Ltd. and Subsidiaries

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(REVIEWED BUT UNAUDITED)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

(22)Equity

(a)Common stock

The Company's had 150,000 thousand authorized shares of which 135,587 thousand shares, 135,221 thousand shares and 135,214 thousand shares were issued as of March 31, 2018, December 31, 2017 and March 31, 2017, respectively, each at par value of NT\$10. Each share possesses one voting right and a right to receive dividends.

During 2016, the unsecured convertible bonds in amount of NT\$815,700 thousand were converted into 4,914,070 shares at par value of NT\$49,141 thousand.

During 2017, the unsecured convertible bonds in amount of NT\$1,100 thousand were converted into 6,849 shares at par value of NT\$69 thousand. In the first quarter of 2018, the unsecured convertible bonds in amount of NT\$58,700 thousand were converted into 365,489 shares at par value of NT\$3,655 thousand. These shares have not yet been legally registered for the capital change as of March 31, 2018. While the Board has resolved in a meeting held on April 17, 2018 the measurement date to be at April 20, 2018.

(b)Capital reserve

Source of capital reserve	As of		
	Mar. 31, 2018	Dec. 31, 2017	Mar. 31, 2017
Treasury share transactions	\$4,363	\$4,363	\$4,363
Convertible bonds—share option	5,134	7,792	7,842
Additional paid-in capital	845,665	788,091	787,016
Total	\$855,162	\$800,246	\$799,221

According to Taiwan Company Act, the capital reserve shall not be used except for making good the deficit of the Company. When a company incurs no loss, it may distribute the capital reserves related to the income derived from the issuance of new shares at a premium or income from endowments received by the Company. The distribution could be made in cash or in the form of dividend shares to its shareholders in proportion to the number of shares being held by each of them.

(c) Treasury stock

On January 3, 2017, the Company's board resolved to buy its own shares as treasury stocks for transferring to its employee. The repurchase period is from January 4, 2017 to March 3, 2017 and the share volume to be brought back are 3,000,000 shares with the unit price interval of NT\$118 to NT\$349.5. As of the end of the repurchase period, the number of shares repurchased were 508,000 shares and the average repurchase unit price NT\$179.26. The carrying value of treasury stock as of March 31, 2018 was NT\$91,062 thousand.

(d) Retained earnings and dividend policy

A. Retained earnings

According to the company articles, both the Company and Pro-partner Inc. shall distribute their annual earnings, if any, in the sequence listed below.

- a. Payment of all taxes and dues;
- b. Making up loss for preceding years, if any;
- c. Set aside 10% of the remaining amount after deducting items (a) and (b) as legal reserve;
- d. Set aside or reverse special reserve in accordance with law and regulations; and
- e. The distribution of the remaining portion, if any, will be recommended by the Board of Directors and resolved in the shareholders' meeting.

B. Dividend policy

The Company's dividend policy shall be determined pursuant to the factors, such as the investment environment, capital requirement, domestic and overseas competition environment, current and future business development plan, as well as shareholders' interests. The distribution of shareholders dividend shall be not lower than 60% remaining current-year earnings. However, the shareholders may resolve not to distribute dividends if the accumulated earnings were lower than 10% of the paid-in capital. The dividend can be distributed by cash, stock or both while at least 10% of total dividends shall be in cash.

C. Legal reserve

According to Taiwan's Company Act, the Company needs to set aside an amount as legal reserve unless where such legal reserve amounts to the amount of total authorized capital. The legal reserve can be used to make good the deficit. When the Company incurs no loss, it may distribute the portion of legal reserve which exceeds 25% of the paid-in capital by issuing new shares or by cash in proportion to the number of shares being held by each of the shareholders.

D. Special reserve

Following the adoption of TIFRS, the Taiwan FSC on April 6, 2012 issued Order No. Financial-Supervisory-Securities-Corporate-1010012865, which sets out the following provisions for compliance:

On a public company's first-time adoption of the TIFRS, for any unrealized revaluation gains and cumulative translation adjustments (gains) recorded to shareholders' equity that the Company elects to transfer to retained earnings by application of the exemption under IFRS 1, the Company shall set aside an equal amount of special reserve. Following a company's adoption of the TIFRS for the preparation of its financial reports, when distributing distributable earnings, it shall set aside to special reserve, from the profit/loss of the current period and the undistributed earnings from the previous period, an amount equal to "other net deductions from shareholders' equity for the current fiscal year, provided that if the Company has already set aside special reserve according to the requirements in the preceding point, it shall set aside supplemental special reserve based on the difference between the amount already set aside and other net deductions from shareholders' equity. For any subsequent reversal of other net deductions from shareholders' equity, the amount reversed may be distributed.

- E. Details of the Company's 2017 and 2016 earnings distribution and dividends per share as approved in the Board of Director meeting held on 9 March 2018 and in the shareholders' meeting held on June 13, 2017 were listed as follows:

	Appropriation of earnings		Dividend per share (in NT\$)	
	2017	2016	2017	2016
Legal reserve	\$135,194	\$129,677		
Common stock—cash dividend	903,199	862,120	6.7	6.4

Grape King Bio Ltd. and Subsidiaries

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(REVIEWED BUT UNAUDITED)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

As to the details of estimation regarding employee's and directors' compensation, please refer to Note 6(24) to the financial statements.

- F. Information regarding Pro-Partner's 2017 and 2016 earnings distribution and dividends per share as approved in the annual shareholders' meeting held on April 19, 2018 and April 27, 2017, respectively, were listed as follows:

	Appropriation of earnings		Dividend per share (in NT\$)	
	2017	2016	2017	2016
Legal reserve	\$145,698	\$147,538		
Common stock—cash dividend	1,310,978	1,062,201	74.49	60.35

- G. Non-controlling interests

	For three-month period ended March 31,	
	2018	2017
Beginning balance	\$1,132,726	\$974,937
Profit attributable to non-controlling interests	115,475	122,685
Ending balance	\$1,248,201	\$1,097,622

- (23) Operating revenue

	For three-month period ended March 31,	
	2018(note)	2017
Sale of goods	\$1,666,489	\$1,927,387
Revenue arising from rendering of services	265,937	76,542
Total	\$1,932,426	\$2,003,929

Note: The Group has adopted IFRS 15 from 1 January 2018. The Group elected to apply the standard retrospectively by recognizing the cumulative effect of initially applying the standard at the date of initial application (1 January 2018).

Grape King Bio Ltd. and Subsidiaries

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(REVIEWED BUT UNAUDITED)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

The Group has adopted IFRS 15 from 1 January 2018. Analysis of revenue from contracts with customers during the year is as follows:

(1) Disaggregation of revenue

	<u>MLM</u>	<u>Distribution</u>	<u>OEM</u>	<u>Total</u>
Sale of goods	\$1,584,326	\$58,351	\$23,812	\$1,666,489
Revenue arising from rendering of services	-	-	265,937	265,937
Total	<u>\$1,584,326</u>	<u>\$58,351</u>	<u>\$289,749</u>	<u>\$1,932,426</u>
Revenue recognition point:				
At a point in time	<u>\$1,584,326</u>	<u>\$58,351</u>	<u>\$289,749</u>	<u>\$1,932,426</u>

(2) Contract balances

A. Contract liabilities - current

	<u>Beginning balance</u>	<u>Ending balance</u>	<u>Difference</u>
Sales of goods	\$1,293	\$5,728	\$4,435
Revenue arising from rendering of services	81,792	72,774	(9,018)
Total	<u>\$83,085</u>	<u>\$78,502</u>	<u>\$(4,583)</u>

During the period, contract liabilities decreased as performance obligations are partially satisfied and NT\$4,583 thousand included in the contract liability balance at the beginning of the period was recognized as revenue during the period.

(3) Assets recognized from costs to fulfil a contract: None.

Grape King Bio Ltd. and Subsidiaries

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(REVIEWED BUT UNAUDITED)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

(24) Schedule of employee benefits, depreciation and amortization by function during the three-month periods ended March 31, 2018 and 2017:

	For three-month period ended March 31,					
	2018			2017		
	Operating costs	Operating expenses	Total	Operating costs	Operating expenses	Total
Employee benefits expense						
Salaries & wages	\$51,737	\$191,770	\$243,507	\$42,586	\$192,156	\$234,742
Labor and health insurance	4,272	7,144	11,416	3,289	7,519	10,808
Pension	3,780	3,081	6,861	2,658	2,763	5,421
Other employee benefits	2,099	2,354	4,453	1,630	4,587	6,217
Depreciation	35,531	21,996	57,527	33,290	19,771	53,061
Amortization	-	1,742	1,742	-	1,592	1,592

According to the resolution, 6%~8% of profit of the current year is distributable as employees' compensation and no higher than 2% of profit of the current year is distributable as remuneration to directors and supervisors. However, the company's accumulated losses shall have been covered. The Company may, by a resolution adopted by a majority vote at a meeting of Board of Directors attended by two-thirds of the total number of directors, have the profit distributable as employees' compensation in the form of shares or in cash; and in addition thereto a report of such distribution is submitted to the shareholders' meeting. Information on Board of Directors' resolution regarding employees' compensation and remuneration to directors and supervisors can be obtained from "Market Observation Post System" on the website of TWSE.

Based on profit of the three-month period ended March 31, 2018, the Company has made an accrual 8% and 2% of profit as employees' compensation and remuneration to directors and supervisors, respectively, amounting to NT\$24,161 thousand and NT\$6,040 thousand and recorded under the caption of salary & wage. If employee compensation is distributed in form of share, the number of shares to be distributed shall be calculated based on the closing trade price on the date prior to the board resolution date. If the estimated amounts differ from the actual distribution resolved by the Board meeting, the Company will record the difference as an adjustment to current income.

Based on profit of the three-month period ended March 31, 2017, the Company has made an accrual 8% and 2% of profit as employees' compensation and remuneration to directors and

supervisors, respectively, amounting to NT\$24,355 thousand and NT\$6,089 thousand and recorded under the caption of salary & wage. If the estimated amounts differ from the actual distribution resolved by the Board of Directors, the Company will recognize the change as an adjustment to current income.

The Company's Board of directors, in a meeting held on February 22, 2018, have approved the Company's 2017 employee compensation and remuneration to directors and supervisors, all in cash, to be NT\$127,470 thousand and NT\$31,867 thousand, respectively, were consistent with amounts recognized by the company.

In addition, the Articles of Incorporation of Pro-partner Inc. states that, after the profit for current year be used to cover accumulated loss if any, 4% of the remaining amount is distributed as the employee's compensation and no more than 5% as the remuneration to directors and supervisors.

Pro-partner Inc., estimated the employees compensation and remuneration to directors amounting to NT\$15,862 thousand and NT\$19,827 thousand, respectively, for the three-month period ended March 31, 2018. If the estimated amounts differ from the actual distribution resolved by the Board of Directors, the Company will recognize the change as an adjustment to current income.

Pro-partner Inc., estimated the employees compensation and remuneration to directors amounted to NT\$16,242 thousand and NT\$20,303 thousand, respectively, for the three-month period ended March 31, 2017. If the estimated amounts differ from the actual distribution resolved by the Board of Directors, the Company will recognize the change as an adjustment to current income.

Pro-partner Inc.'s distributions of employee compensation and remuneration to directors for 2017 amounting NT\$78,579 thousand and NT\$98,224 thousand approved by the Board of Directors were consistent with the amounts recognized.

Grape King Bio Ltd. and Subsidiaries

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(REVIEWED BUT UNAUDITED)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

(25) Non-operating incomes and expenses

(a) Other incomes

	For three-month period ended March 31,	
	2018	2017
Interest income from bank deposits	\$1,809	\$995
Rental revenue	4,715	4,330
Other Income	13,921	14,882
Total	<u>\$20,445</u>	<u>\$20,207</u>

(b) Other gains and losses

	For three-month period ended March 31,	
	2018	2017
Loss from disposal of fixed assets	\$-	\$(373)
Foreign exchange loss, net	(1,949)	(1,112)
Gain from financial assets at fair value through P/L (Note)	111	160
Others	(32)	(22)
Total	<u>\$(1,870)</u>	<u>\$(1,347)</u>

Note: Balance in current period was arising from financial assets mandatorily measured at fair value through profit or loss and balance in prior period was arising from held for trading investment.

(c) Finance costs

	For three-month period ended March 31,	
	2018	2017
Imputed interest on deposit	\$64	\$47
Interest on borrowings from bank	2,966	3,555
Interest on bonds payable	808	812
Total	<u>\$3,838</u>	<u>\$4,414</u>

(26) Components of other comprehensive income

For the three-month period ended March 31, 2018

	<u>Arising during the period</u>	<u>Income tax relating to components of other comprehensive income</u>	<u>Other comprehensive income, net of tax</u>
Not to be reclassified to profit or loss in subsequent periods:			
Unrealized gains (losses) from equity instruments investments measured at fair value through other comprehensive income	\$(1,723)	\$-	\$(1,723)
To be reclassified to profit or loss in subsequent period:			
Exchange differences resulting from translating financial statements of foreign operations	11,084	-	11,084
Total of other comprehensive income	<u>\$9,361</u>	<u>\$-</u>	<u>\$9,361</u>

For the three-month period ended March 31, 2017

	<u>Arising during the period</u>	<u>Income tax relating to components of other comprehensive income</u>	<u>Other comprehensive income, net of tax</u>
To be reclassified to profit or loss in subsequent period:			
Exchange differences Resulting from translating financial statements of foreign operations	\$(23,927)	\$-	\$(23,927)

Grape King Bio Ltd. and Subsidiaries

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(REVIEWED BUT UNAUDITED)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

(27)Income tax

Based on the amendments to the Income Tax Act announced on 7 February 2018, the Company's applicable corporate income tax rate for the year ended 31 December 2018 has changed from 17% to 20%. The corporate income surtax on undistributed retained earnings has changed from 10% to 5%.

The major components of income tax expense (income) are as follows:

Income tax expense (income) recognized in profit or loss

	For three-month period ended March 31,	
	2018	2017
Current income tax expense (benefit):		
Current income tax charge	\$98,504	\$78,347
Adjustments in respect of current income tax of prior periods	-	1,275
Deferred income tax expense (benefit):		
Deferred income tax expense (benefit) related to origination and reversal of temporary difference	370	382
The effect of tax rate change	(140)	-
Total income tax expense	<u>\$98,734</u>	<u>\$80,004</u>

Income tax relating to components of other comprehensive income

	For three-month period ended March 31,	
	2018	2017
Deferred tax expense (benefit):		
Unrealized gains (losses) from equity instruments investments measured at fair value through other comprehensive income	\$-	\$-
Exchange differences on translation of foreign operations	-	-
Income tax relating to components of other comprehensive income	<u>\$-</u>	<u>\$-</u>

Tax assessment

As of March 31, 2018, the status of assessment from tax authority for the Company and Pro-partner Inc. are listed as follows:

	<u>Status</u>
The Company	Assessed and approved up to 2016
Pro-partner Inc.	Assessed and approved up to 2015
Rivershine Ltd.	Assessed and approved up to 2016

(28) Earnings per share

Basic earnings per share amounts are calculated by dividing net profit for the year attributable to ordinary equity holders of the parent entity by the weighted average number of ordinary shares outstanding during the year.

Diluted earnings per share amounts are calculated by dividing the net profit attributable to ordinary equity holders of the parent entity by the weighted average number of ordinary shares outstanding during the year plus the weighted average number of ordinary shares that would be issued on conversion of all the dilutive potential ordinary shares into ordinary shares.

	<u>For three-month period ended March 31,</u>	
	<u>2018</u>	<u>2017</u>
(a) Basic earnings per share		
Profit attributable to ordinary equity holders of the Company (in thousand NT\$)	<u>\$260,313</u>	<u>\$258,825</u>
Weighted average number of ordinary shares outstanding for basic earnings per share (in thousand shares)	<u>134,846</u>	<u>134,854</u>
Basic earnings per share (in NT\$)	<u>\$ 1.93</u>	<u>\$1.92</u>

Grape King Bio Ltd. and Subsidiaries

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(REVIEWED BUT UNAUDITED)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

	For three-month period ended March 31,	
	2018	2017
(b) Diluted earnings per share		
Profit attributable to ordinary equity holders of the Company (in thousand NT\$)	\$260,313	\$258,825
Interest expense from convertible bonds (in thousand NT\$)	702	801
Gain or loss on valuation of redemption	63	(52)
Profit attributable to ordinary equity holders of the Company after dilution (in thousand NT\$)	<u>\$261,078</u>	<u>\$259,574</u>
Weighted average number of ordinary shares outstanding for basic earnings per share (in thousand shares)	134,846	134,854
Effect of dilution:		
Employee bonus – stock (in thousand shares)	469	693
Convertible bonds (in thousand shares)	939	1,044
Weighted average number of ordinary shares outstanding after dilution (in thousand shares)	<u>136,254</u>	<u>136,591</u>
Diluted earnings per share (in NT\$)	<u>\$ 1.92</u>	<u>\$1.90</u>

There were no other transaction involving ordinary shares or potential ordinary shares between the balance sheet date and the completion date of the Company's consolidated financial statements.

(29) Subsidiary that has material non-controlling interests

Financial information of subsidiary that has material non-controlling interests is as below:

Proportion of equity interest held by non-controlling interests:

The summarized financial information of this subsidiary is provided below. This information is based on amounts before inter-company eliminations.

Grape King Bio Ltd. and Subsidiaries

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(REVIEWED BUT UNAUDITED)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

Name	Country of incorporation and operation	As of		
		Mar. 31, 2018	Dec. 31, 2017	Mar. 31, 2017
Pro-partner	Republic of China	40%	40%	40%

	As of		
	Mar. 31, 2018	Dec. 31, 2017	Mar. 31, 2017
Accumulated balances of material non-controlling interest:			
Pro-partner	\$1,248,201	\$1,132,726	\$1,097,622

	For three-month period ended March 31,	
	2018	2017
Profit/(loss) allocated to material non-controlling interest:		
Pro-partner	\$115,475	\$122,685

The summarized financial information of this subsidiary is provided below. This information is based on amounts before inter-company eliminations.

Summarized information of profit or loss is as follows:

	For three-month period ended March 31,	
	2018	2017
Operating revenue	\$1,584,326	\$1,841,981
Profit/loss from continuing operation	\$288,688	\$306,712
Total comprehensive income for the period	\$288,688	\$306,712

Summarized information of financial position is as follows:

	As of		
	Mar. 31, 2018	Dec. 31, 2017	Mar. 31, 2017
Current assets	\$1,482,779	\$1,404,149	\$1,684,163
Non-current assets	3,696,473	3,567,526	3,549,498
Current liabilities	(1,544,477)	(1,617,545)	(1,557,169)
Non-current liabilities	(514,272)	(522,315)	(932,439)

Grape King Bio Ltd. and Subsidiaries

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(REVIEWED BUT UNAUDITED)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

Summarized cash flow information is as follows:

	For three-month period ended March 31,	
	2018	2017
Operating activities	\$248,541	\$180,274
Investing activities	(144,496)	(10,295)
Financing activities	(8,028)	11,828
Net increase/(decrease) in cash and cash equivalents	96,017	181,807

7. Related party transactions

(1) Name of related party and the relation

Name of related party	Relation
Laifu Limited Company (Laifu)	Related party in substance
Pu Hsing Enterprise Co., Ltd. (Pu Hsing)	A director of Pro-partner
Taipei City Pro-partner Technology and Human Development Foundation (Pro-partner Foundation)	Pro-partner is its sole founder.
Integrate Chinese Medicine Holdings Ltd.	Supervisor of Pro-partner
Chih-Sheng Chang	A supervisor of the Company
Chang-Yeh Tseng	The Chairman of Pro-partner
Mei-Ching Tseng	General manager of Pro-partner
Pu-Lin Ltd. (Pu-Lin)	Related party in substance of Pro-partner (NOTE)

NOTE: Please refer to Note 9(3).

(2) Significant transactions with related parties

a. Sales

	For three-month period ended March 31,	
	2018	2017
Laifu	\$-	\$(17)
Pu Hsing	331	336
Total	\$331	\$319

Grape King Bio Ltd. and Subsidiaries

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(REVIEWED BUT UNAUDITED)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

The above mentioned parties are the exclusive distributors for beverage products of the Company, and the Multi-level marketing (MLM) members of the subsidiaries. The sales price for the other related parties was determined based on mutual consent and the price for the third-party MLM member customers. There is no significant difference regarding the terms and conditions for the other related parties and for the third-parties.

b. Amounts owed by related parties

	As of		
	Mar. 31, 2018	Dec. 31, 2017	Mar. 31, 2017
Laifu	\$-	\$-	\$159
Less: loss allowance	-	-	-
Net	\$-	\$-	\$159

c. Account payables to related parties

	As of		
	Mar. 31, 2018	Dec. 31, 2017	Mar. 31, 2017
Laifu	\$-	\$-	\$115

d. Other payables to related parties

	As of		
	Mar. 31, 2018	Dec. 31, 2017	Mar. 31, 2017
Pu Hsing	\$19,708	\$16,402	\$19,939
Integrate Chinese Medicine Holdings Ltd.	19,675	16,371	19,908
Total	\$39,383	\$32,773	39,847

e. Temporary Receipts

	As of		
	Mar. 31, 2018	Dec. 31, 2017	Mar. 31, 2017
Mei-Ching Tseng	\$17,607	\$17,607	\$-

Grape King Bio Ltd. and Subsidiaries

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(REVIEWED BUT UNAUDITED)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

f. Selling and marketing – commission

	For three-month period ended March 31,	
	2018	2017
Pu Hsing	\$99	\$97

The above related parties are MLM members of subsidiary. The calculation and payment terms are the same as with the general membership in accordance with the regulations of Business Manual.

g. General and administrative expenses – rental

	For three-month period ended March 31,	
	2018	2017
Pu-Lin	\$1,050	\$1,050
Chih-Sheng Chang	360	360
Chang-Yeh Tseng	360	360
Total	\$1,770	\$1,770

The rental paid to the above related parties and normal rental prices were similar and comparable. The term of payment was either on a monthly basis or in full at beginning of each year except for the payment to Pu-Lin being in advance for six months. Prepaid rents amounted to NT\$220 thousand, NT\$1,269 thousand, and NT\$220 thousand as of March 31, 2018, December 31, 2017 and March 31, 2017, respectively.

h. General and administrative – donations

	For the three-month period ended March 31,	
	2018	2017
Pro-partner Foundation	\$-	\$200

Grape King Bio Ltd. and Subsidiaries

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(REVIEWED BUT UNAUDITED)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

i. Revenue from rental assets

	For three-month period ended March 31,	
	2018	2017
Pu Hsing	\$3	\$3
Pro-partner Foundation	3	3
Total	\$6	\$6

The rental from the above related parties and normal rental prices were similar and comparable. The term of collection was either in a monthly installment or in full at the beginning of each year.

j. Key management personnel compensation

	For three-month period ended March 31,	
	2018	2017
Short-term employee benefits	\$19,033	\$15,562
Post-employment benefits	88	66
Total	\$19,121	\$15,628

8. Assets pledged as collaterals

The following assets are pledged as collaterals.

Assets pledged	As of			Purpose of pledge
	Mar. 31, 2018	Dec. 31, 2017	Mar. 31, 2017	
Property, plant and equipment-land	\$1,921,301	\$1,921,301	\$2,121,928	For long-term and short-term secured loans.
Property, plant and equipment-building	1,104,719	1,032,702	1,049,023	For long-term and short-term secured loans.
Debt investments without active market — pledged time deposits	(Note)	4,460	4,460	For leasing land and operating center from Science-based Park.

Grape King Bio Ltd. and Subsidiaries

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(REVIEWED BUT UNAUDITED)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

Financial assets measured at amortized cost	4,460	(Note)	(Note) For leasing land and operating center from Science-based Park.
Total	<u>\$3,030,480</u>	<u>\$2,958,463</u>	<u>\$3,175,411</u>

Note: The Group adopted IFRS 9 since 1 January 2018. The Group elected not to restate prior periods in accordance with the transition provision in IFRS 9.

9. Commitments and contingencies

- (1) The Company's guarantee notes issued to banks for credit lines amounted to NT\$250,000 thousand.
- (2) The Company entered into a contract for plant and machinery. Total contract amount is NT\$1,055,000 thousand while NT\$732,293 thousand remained unpaid as of March 31, 2018.
- (3) For operational needs, Pro-partner has to establish operational bases in Taipei, Taoyuan, Hsinchu, Fengyuan, Taichung, Kaohsiung, Pingzhen, Jhongli, Hualien and Tainan. All offices, except for Taipei operational center which is a business building purchased and owned by Pro-partner, were leased from others. The information concerning the operating leases sustained as of March 31, 2018 is listed below:

Operation Sites	Lessor	The lease term	Monthly rental
Taipei City	Uni-President Enterprises Corporation	2013.5.1~2018.6.30	\$570
Taipei City	Concept Business Center Ltd.	2017.5.1~2018.5.18	20
Taoyuan City	Taoyuan Irrigation Association	2016.11.9~2019.11.8	180
Hsinchu City	Lin, Zhuang-Long, Wu, Yi-Wan	2016.11.1~2021.10.31	320
Fengyuan Dist.	Lin, Fen-Ling	2017.6.1~2020.5.31	70
Taichung City	Pu-Lin Ltd. (NOTE)	2007.11.1~2027.11.1	220
Taichung City	Pu-Lin Ltd. (NOTE)	2010.4.1~2030.3.31	129
Kaohsiung City	The Company	2018.1.1~2020.12.31	236
Pingzhen Dist.	The Company	2018.4.1~2019.3.31	48
Chungli Dist.	The Company	2017.4.1~2022.3.31	1
HuaLian City	Liou, Chuen-Hou, Liou, Chuen-Lung	2017.9.1~2019.8.31	130
Tainan City	Cathay Life Insurance Company, Ltd.	2016.3.21~2021.7.31	799

Grape King Bio Ltd. and Subsidiaries

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(REVIEWED BUT UNAUDITED)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

NOTE:

According to the general manager of Pro-partner Inc., Pu-Lin Ltd. has been funded solely by herself while it has registered under the name of Yide Lin as the sole director and shareholder. On August 29, 2017, Taiwan Taichung District Court decides that NT\$8.5 million out of total capital contribution of NT\$12.5 million shall be changed and registered for under the name of the general manager of Pro-partner Inc. As a result, the rental expenditures that Pro-partner Inc. paid to Pu-Lin Ltd. were accounted for as related party transactions and disclosed in Note 7 to these financial statements. Though, the general manager of Pro-partner Inc. appeals from the Court decision. As of the issuance date of these consolidated financial statements, no further progress from the Court is obtained yet.

- (4) Pro-partner Inc. has purchased the software rights of the cloud version of the direct marketing information management system from WELLAN SYSTEM CO., LTD., in August 2016. The total contract price is in amount of NT\$19,780 thousand to be paid in 24 installments during the period of 2 years. As of March 31, 2018, the software system mentioned above was not completed yet.
- (5) Pro-partner Inc. has entered into certain agreements for computer software and hardware leasing and maintenance contracts on February 1, 2008. Pro-partner Inc. also has entered into additional software leasing and maintenance contracts for logistics management on January 1, 2013 with "FINE EAGLE INVESTMENTS LIMITED" for the services provided by WELLAN SYSTEM CO., LTD., The general manager of Pro-partner Inc. has paid the related commission in amount of \$17,607 thousand to Pro-partner on behalf of "FINE EAGLE INVESTMENTS LIMITED" due to an Investigation Bureau case against her. As the investigation is not yet finalized, Pro-partner recorded the payment under the caption of temporary receipts. Pro-partner will either return the payment or reclassify it for proper account based on the Court's decision.
- (6) In December 2016, the Company was affected by news events suspected of changing label on overdue goods. As this case is in interrogation by authority, it is not feasible to reasonably assess the impact of the event on the Company as of the issuance date of the consolidated financial statements.

Grape King Bio Ltd. and Subsidiaries

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(REVIEWED BUT UNAUDITED)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

10. Losses due to major disasters

None.

11. Significant subsequent events

None.

12. Financial instruments

(1) Categories of financial instruments

<u>Financial assets</u>	As of		
	Mar. 31, 2018	Dec. 31, 2017	Mar. 31, 2017
Financial asset at fair value through P/L:			
Held for trading	(Note 1)	\$70,307	\$240,186
Mandatorily measured at Fair value through P/L	170,465	(Note 1)	(Note 1)
Designated financial asset at fair value through P/L	-	69	139
Subtotal	170,465	70,376	240,325
Financial assets at fair value through OCI	16,664	(Note 1)	(Note 1)
Available-for-sale financial assets			
(Note 2)	(Note 1)	28,028	28,028
Financial assets measured at amortized cost (Note 3)	2,150,720	(Note 1)	(Note 1)
Loans and receivables (Note 4)	-	2,271,512	2,153,181
Total	\$2,337,849	\$2,369,916	\$2,421,534

<u>Financial liabilities</u>	As of		
	Mar. 31, 2018	Dec. 31, 2017	Mar. 31, 2017
Financial liabilities at amortized cost:			
Short-term loans	\$450,000	\$300,000	\$-
Notes payable	2,775	7,207	1,480
Accounts payable (related parties included)	166,695	316,108	172,851

Grape King Bio Ltd. and Subsidiaries

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(REVIEWED BUT UNAUDITED)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

Other payables	1,333,873	1,618,259	1,351,275
Other payables – related parties	39,383	32,773	39,847
Bonds payable (current portion included)	113,355	171,207	169,794
Long-term loans (current portion included)	542,603	550,644	980,831
Other long-term payables	15,763	16,032	16,339
Total	<u>\$2,664,447</u>	<u>\$3,012,230</u>	<u>\$2,732,417</u>

Note:

- 1) The Group adopted IFRS 9 since 1 January 2018. The Group elected not to restate prior periods in accordance with the transition provision in IFRS 9.
- 2) Balances as at 31 December 2017 and 31 March 2017 including financial assets measured at cost.
- 3) Including cash and cash equivalents, financial assets measured at amortized cost, notes receivable, trade receivables and other receivables.
- 4) Including cash and cash equivalents, notes receivable, trade receivables, bond investments with no active market and other receivables.

(2) Financial risk management objectives and policies

The Group's principal financial risk management objective is to manage the market risk, credit risk and liquidity risk related to its operating activities. The Group identifies measures and manages the aforementioned risks based on the Group's policy and risk appetite.

The Group has established appropriate policies, procedures and internal controls for financial risk management. Before entering into significant transactions, approval process by the Board of Directors must be carried out based on related protocols and internal control procedures. The Group complies with its financial risk management policies at all times.

(3) Market risk

Market risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of the changes in market prices. Market prices comprise currency risk, interest rate risk and other price risk (such as equity risk).

In practice, it is rarely the case that a single risk variable will change independently from other risk variables. There are usually interdependencies between risk variables. However the sensitivity analysis disclosed below does not take into account the interdependencies between risk variables.

Foreign currency risk

The Group's exposure to the risk of changes in foreign exchange rates relates primarily to the Group's operating activities (when revenue or expense are denominated in a different currency from the Group's functional currency) and the Group's net investments in foreign subsidiaries.

The Group has certain foreign currency receivables to be denominated in the same foreign currency with certain foreign currency payables, therefore natural hedge is received. Furthermore, as net investments in foreign subsidiaries are for strategic purposes, they are not hedged by the Group.

The foreign currency sensitivity analysis of the possible change in foreign exchange rates on the Group's profit is performed on significant monetary items denominated in foreign currencies as at the end of the reporting period. The Group's foreign currency risk is mainly related to the volatility in the exchange rates for foreign currency USD. The information of the sensitivity analysis is as follows:

When NTD strengthens/weakens against foreign currency USD by 10%, the profit before tax for the three-month periods ended March 31, 2018 and 2017 decreased/increased by NT\$10,184 thousand and NT\$11,476 thousand, respectively.

Interest rate risk

Interest rate risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Group's exposure to the risk of changes in market interest rates relates primarily to the Group's loans and receivables at variable interest rates.

The interest rate sensitivity analysis is performed on items exposed to interest rate risk as at the end of the reporting period, including investments with variable interest rates. At the reporting date, a change of 0.1% of interest rate in a reporting period could cause the profit

before tax for the three-month periods ended March 31, 2018 and 2017 to increase/decrease by NT\$261 thousand and decrease/increase NT\$250 thousand, respectively.

Equity price risk

The fair value of the Group's unlisted equity securities and monetary fund are susceptible to market price risk arising from uncertainties about future values of the investment securities. The Group's unlisted equity securities are classified under available-for-sale financial assets.

The Group manages the equity price risk through diversification and placing limits on individual and total equity instruments. Reports on the equity portfolio are submitted to the Group's senior management on a regular basis. The Group's Board of Directors reviews and approves all equity investment decisions.

At the reporting date, a change of 5% in net asset value of the monetary fund held for trading could increase/decrease the Group's profit before tax for the three-month periods ended March 31, 2018 and 2017 by NT\$8,523 thousand and NT\$12,009 thousand, respectively.

(4) Credit risk management

Credit risk is the risk that the counterparty will not meet its obligations under a contract, leading to a financial loss. The Group is exposed to credit risk from operating activities (primarily for accounts receivables and notes receivables) and from its financing activities, including bank deposits and other financial instruments.

Customer credit risk is managed by each business unit subject to the Group's established policy, procedures and control relating to customer credit risk management. Credit limits are established for all customers based on their financial position, rating from credit rating agencies, historical experience, prevailing economic condition and the Group's internal rating criteria etc. Certain customer's credit risk will also be managed by taking credit enhancing procedures, such as requesting for prepayment.

There is no concentration of credit risk of a single customer for the three-month periods ended March 31, 2018 and 2017. Therefore, the credit risk is insignificant.

Credit risk from balances with banks, fixed income securities and other financial instruments is managed by the Group's treasury in accordance with the Group's policy. The Group only

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(REVIEWED BUT UNAUDITED)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

transacts with counterparties approved by the internal control procedures, which are banks and financial institutions, companies and government entities with good credit rating and with no significant default risk. Consequently, there is no significant credit risk for these counterparties.

(5) Liquidity risk management

The Group's objective is to maintain a balance between continuity of funding and flexibility through the use of cash and cash equivalents and highly liquid equity investments. The table below summarizes the maturity profile of the Group's financial liabilities based on the contractual undiscounted payments and contractual maturity. The payment amount includes the contractual interest. The undiscounted payment relating to borrowings with variable interest rates is extrapolated based on the estimated interest rate yield curve as of the end of the reporting period.

Non-derivative financial instruments

	Less than 6 months	6 to 12 months	1 to 2 years	2 to 5 years	More than 5 years	Total
<u>As of March 31, 2018</u>						
Short-term loans	\$450,130	\$-	\$-	\$-	\$-	\$450,130
Notes payable	2,775	-	-	-	-	2,775
Accounts payable(related parties included)	166,695	-	-	-	-	166,695
Bonds payable(current portion included)	114,253	-	-	-	-	114,253
Other payables(related parties included)	1,311,329	61,927	-	-	-	1,373,256
Long-term payables	-	-	-	-	15,763	15,763
Long-term loans(current portion included)	20,284	20,413	40,825	122,476	413,670	617,668
<u>As of December 31, 2017</u>						
Short-term loans	\$300,193	\$-	\$-	\$-	\$-	\$300,193
Notes payable	6,513	694	-	-	-	7,207
Accounts payable	316,108	-	-	-	-	316,108

Grape King Bio Ltd. and Subsidiaries

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(REVIEWED BUT UNAUDITED)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

Other payables(related parties included)	1,444,845	206,187	-	-	-	1,651,032
Bonds payable(current portion included)	-	173,394	-	-	-	173,394
Long-term loans(current portion included)	20,093	20,413	40,825	122,476	423,877	627,684
Long-term payables	-	-	-	-	16,032	16,032
<u>As of March 31, 2017</u>						
Notes payable	\$1,480	\$-	\$-	\$-	\$-	\$1,480
Accounts payable (related parties included)	172,851	-	-	-	-	172,851
Bonds payable	-	-	174,502	-	-	174,502
Other payables(related parties included)	1,246,777	144,345	-	-	-	1,391,122
Long-term payables	-	-	-	-	16,339	16,339
Long-term loans (current portion included)	30,764	36,822	73,644	220,933	755,580	1,117,743

(6) Reconciliation of liabilities arising from financing activities

Reconciliation of liabilities as at 31 March 2018:

	Short-term borrowings	Long-term borrowings	Guarantee deposit received	Total liabilities from financing activities
As at 1 Jan. 2018	\$300,000	\$550,644	\$23,382	\$874,026
Cash flows	150,000	(8,041)	473	142,432
As at 31 Mar. 2018	\$450,000	\$542,603	\$23,855	\$1,016,458

Reconciliation of liabilities as at 31 March 2017: Not applicable

(7) Fair values of financial instruments

- (a) The methods and assumptions applied in determining the fair value of financial instruments:

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The following methods and assumptions were used by the Group to measure or disclose the fair values of financial assets and financial liabilities:

- a. The carrying amount of cash and cash equivalents, accounts receivables, accounts payable and other current liabilities approximate their fair value due to their short maturities.
- b. For financial assets and liabilities traded in an active market with standard terms and conditions, their fair value is determined based on market quotation price (including listed equity securities, beneficiary certificates, bonds and futures etc.) at the reporting date.
- c. Fair value of equity instruments without market quotations (including private placement of listed equity securities, unquoted public company and private company equity securities) are estimated using the market method valuation techniques based on parameters such as prices based on market transactions of equity instruments of identical or comparable entities and other relevant information (for example, inputs such as discount for lack of marketability, P/E ratio of similar entities and Price-Book ratio of similar entities).
- d. Fair value of debt instruments without market quotations, bank loans, bonds payable and other non-current liabilities are determined based on the counterparty prices or valuation method. The valuation method uses DCF method as a basis, and the assumptions such as the interest rate and discount rate are primarily based on relevant information of similar instrument (such as yield curves published by the GreTai Securities Market, average prices for Fixed Rate Commercial Paper published by Reuters and credit risk, etc.)

Grape King Bio Ltd. and Subsidiaries

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(REVIEWED BUT UNAUDITED)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

(b) Fair value of financial instruments measured at amortized cost

The carrying amount of the Group's financial assets and liabilities measured at amortized cost approximate their fair value.

	Carrying value			Fair value		
	31		31 March 2017	31		31 March 2017
	31 March 2018	December 2017		31 March 2018	December 2017	
Financial liabilities						
Bonds payable	\$-	\$-	\$169,794	\$-	\$-	\$170,585
Current portion of bonds payable	113,355	171,207	-	113,649	171,876	-

(c) Fair value measurement hierarchy for financial instruments

Please refer to Note 12(9) for fair value measurement hierarchy for financial instruments of the Group.

(8) Derivative financial instruments

The Group's derivative financial instruments include embedded derivatives. The related information for derivative financial instruments not qualified for hedge accounting and not yet settled as of March 31, 2018 and 2017 is as follows:

Embedded derivatives

The embedded derivatives arising from issuing convertible bonds have been separated from the host contract and carried at fair value through profit or loss. Please refer to Note 6(17) for further information on this transaction.

(9) Fair value measurement hierarchy

(a) Fair value measurement hierarchy

All asset and liabilities for which fair value is measured or disclosed in the financial statements are categorized within the fair value hierarchy, based on the lowest level

Grape King Bio Ltd. and Subsidiaries

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(REVIEWED BUT UNAUDITED)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

input that is significant to the fair value measurement as a whole. Level 1, 2 and 3 inputs are described as follows:

Level 1 – Quoted (unadjusted) market prices in active markets for identical assets or liabilities that the entity can access at the measurement date

Level 2 – Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly

Level 3 – Unobservable inputs for the asset or liability

For assets and liabilities that are recognized in the financial statements on a recurring basis, the Group determines whether transfers have occurred between Levels in the hierarchy by re-assessing categorization at the end of each reporting period.

(b) Fair value measurement hierarchy of the Group's assets and liabilities

The Group does not have assets that are measured at fair value on a non-recurring basis. Fair value measurement hierarchy of the Group's assets and liabilities measured at fair value on a recurring basis is as follows:

As of March 31, 2018

	Level 1	Level 2	Level 3	Total
Financial assets:				
Financial assets at fair value through profit or loss				
Monetary fund	\$170,465	\$-	\$-	\$170,465
Embedded Derivatives	-	-	-	-
Financial assets at fair value through other comprehensive income				
Stocks	-	-	16,664	16,664
Total	<u>\$170,465</u>	<u>\$-</u>	<u>\$16,664</u>	<u>\$187,129</u>

Grape King Bio Ltd. and Subsidiaries

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(REVIEWED BUT UNAUDITED)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

As of December 31, 2017

	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>	<u>Total</u>
Financial assets:				
Financial assets at fair value through profit or loss				
Monetary fund	\$70,307	\$-	\$-	\$70,307
Embedded derivative	-	-	69	69
Total	<u>\$70,307</u>	<u>\$-</u>	<u>\$69</u>	<u>\$70,376</u>

As of March 31, 2017

	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>	<u>Total</u>
Financial assets:				
Financial assets at fair value through profit or loss				
Monetary fund	\$240,186	\$-	\$-	\$240,186
Embedded derivative	-	-	139	139
Total	<u>\$240,186</u>	<u>\$-</u>	<u>\$139</u>	<u>\$240,325</u>

Transfers between Level 1 and Level 2 during the period

During the three-month periods ended March 31, 2018 and 2017, there were no transfer between Level 1 and Level 2 fair value measurements.

Reconciliation for fair value measurements in Level 3 of the fair value hierarchy for movements during the period of March 31, 2018 and 2017 are as follows:

	<u>Assets</u>		<u>Sub-total</u>
	<u>At fair value through PL</u>	<u>At fair value through OCI</u>	
	<u>Derivatives</u>	<u>Stocks</u>	
Beginning balances as of January 1, 2018	\$69	\$28,028	\$28,097
Retrospectively recognized in other equity at the beginning of the period	-	(9,641)	(9,641)
Bonds conversion	(6)	-	(6)
Total gains and losses recognized for three-month period ended March 31, 2018:			

Grape King Bio Ltd. and Subsidiaries

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(REVIEWED BUT UNAUDITED)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

Amount recognized in profit or loss (presented in “other profit or loss”)	(63)	-	(63)
Amount recognized in OCI (presented in “Unrealized gains (losses) from equity instruments investments measured at fair value through other comprehensive income)	-	(1,723)	(1,723)
Ending balances as of March 31, 2018	\$-	\$16,664	\$16,664

	Assets		
	At fair value through PL	At fair value through OCI	Sub-total
	Derivatives	Stocks	
Beginning balances as of January 1, 2017	\$87	\$-	\$87
Total gains and losses recognized for three-month period ended March 31, 2017:			
Amount recognized in profit or loss (presented in “other profit or loss”)	52	-	52
Ending balances as of March 31, 2017	\$139	\$-	\$139

Total gains and losses recognized in profit or loss for the three-month periods ended March 31, 2018 and 2017 in the table above contain gains and losses related to assets on hand as of March 31, 2018 and 2017 in the amount of NT\$(63) thousand and NT\$52 thousand.

Grape King Bio Ltd. and Subsidiaries

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(REVIEWED BUT UNAUDITED)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

Information on significant unobservable inputs to valuation

Description of significant unobservable inputs to valuation of recurring fair value measurements categorized within Level 3 of the fair value hierarchy is as follows:

As of March 31, 2018

	Valuation techniques	Significant unobservable inputs	Quantitative information	Relationship between inputs and fair value	Sensitivity of the input to fair value
Financial assets: At fair value through profit or loss					
Embedded derivatives	Option pricing model	Volatility	22.92%	The higher the volatility, the higher the fair value of the embedded derivatives.	1% increase (decrease) in the volatility would not impact on the Group's profit or loss.
Financial assets at fair value through other comprehensive income					
Stocks	Market approach	discount for lack of marketability	30.00%	The higher the discount for lack of marketability, the lower the fair value of the stocks	1% increase (decrease) in the discount for lack of marketability would result in decrease (increase) in the Group's equity by NT\$238 thousand

Grape King Bio Ltd. and Subsidiaries

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(REVIEWED BUT UNAUDITED)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

As of December 31, 2017

	Valuation techniques	Significant unobservable inputs	Quantitative information	Relationship between inputs and fair value	Sensitivity of the input to fair value
Financial assets:					
At fair value through profit or loss					
Embedded derivatives	Option pricing model	Volatility	29.31%	The higher the volatility, the higher the fair value of the embedded derivatives.	1% increase (decrease) in the volatility would result in decrease in the Group's profit or loss by NT\$17 /34 thousand

As of March 31, 2017

	Valuation techniques	Significant unobservable inputs	Quantitative information	Relationship between inputs and fair value	Sensitivity of the input to fair value
Financial assets:					
At fair value through profit or loss					
Embedded derivatives	Option pricing model	Volatility	33.45%	The higher the volatility, the higher the fair value of the embedded derivatives.	1% increase (decrease) in the volatility would result in decrease in the Group's profit or loss by NT\$0/35 thousand

(c) Fair value measurement hierarchy of the Group's assets and liabilities not measured at fair value but for which the fair value is disclosed.

Grape King Bio Ltd. and Subsidiaries

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(REVIEWED BUT UNAUDITED)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

As of March 31, 2018

	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>	<u>Total</u>
Financial assets not measured at fair value but for which the fair value is disclosed:				
Investment properties (please refer to Note 6(12))	\$-	\$-	\$247,831	\$247,831
Financial liabilities not measured at fair value but for which the fair value is disclosed:				
Bonds payable (please refer to Note 6(17))	\$-	\$-	\$113,649	\$113,649

As of December 31, 2017

	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>	<u>Total</u>
Financial assets not measured at fair value but for which the fair value is disclosed:				
Investment properties (please refer to Note 6(12))	\$-	\$-	\$247,831	\$247,831
Financial liabilities not measured at fair value but for which the fair value is disclosed:				
Bonds payable (please refer to Note 6(17))	\$-	\$-	\$171,876	\$171,876

As of March 31, 2017

	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>	<u>Total</u>
Financial assets not measured at fair value but for which the fair value is disclosed:				
Investment properties (please refer to Note 6(12))	\$-	\$-	\$247,692	\$247,692
Financial liabilities not measured at fair value but for which the fair value is disclosed:				
Bonds payable (please refer to Note 6(17))	\$-	\$-	\$170,585	\$170,585

Grape King Bio Ltd. and Subsidiaries

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(REVIEWED BUT UNAUDITED)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

(10) Significant assets and liabilities denominated in foreign currencies

Information regarding the significant assets and liabilities denominated in foreign currencies is listed below:

	As of March 31, 2018			As of December 31, 2017		
	Foreign currencies	Foreign exchange rate	NTD	Foreign currencies	Foreign exchange rate	NTD
<u>Financial assets</u>						
Monetary items:						
USD	\$4,434	29.31	\$129,971	\$4,319	29.84	\$128,880
<u>Financial liabilities</u>						
Monetary items:						
USD	\$963	29.22	\$28,135	\$1,227	29.83	\$36,610
<u>As of March 31, 2017</u>						
	Foreign currencies	Foreign exchange rate	NTD			
<u>Financial assets</u>						
Monetary items:						
USD	\$4,409	30.41	\$134,098			
<u>Financial liabilities</u>						
Monetary items:						
USD	\$636	30.41	\$19,338			

The above information is disclosed based on the carrying amount of foreign currency (after conversion to functional currency).

The Company's functional currency is variety. It is not practical to disclose the foreign exchange gains or losses on monetary financial assets and financial liabilities for each currency with significant influence. The Foreign exchange losses of the Company amounted to NT\$1,949 thousand and NT\$1,112 thousand respectively on March 31, 2018 and 2017.

(11) Capital management

The same summarized quantitative information of capital management have been applied in the Company's consolidated financial statements for the three-month period ended March 31, 2018 as those applied in the Company's consolidated financial statements for the year ended December 31, 2017. For the related information please refer to Note 12(10) of the Company's consolidated financial statements for year ended December 31, 2017.

13. Other disclosure

(1) Information at significant transactions

- a. Financing provided to others for the three-month period ended March 31, 2018: None
- b. Endorsement/Guarantee provided to others for the three-month period ended March 31, 2018: Please refer to attachment 1.
- c. Securities held as of March 31, 2018: Please refer to attachment 2.
- d. Individual securities acquired or disposed of with accumulated amount exceeding the lower of NT\$300 million or 20 percent of the capital stock for the three-month period ended March 31, 2018: None
- e. Acquisition of individual real estate with amount exceeding the lower of NT\$300 million or 20 percent of the capital stock for the three-month period ended March 31, 2018: None
- f. Disposal of individual real estate with amount exceeding the lower of NT\$300 million or 20 percent of the capital stock for the three-month period ended March 31, 2018: None
- g. Related party transactions for purchases and sales amounts exceeding the lower of NT\$100 million or 20 percent of the capital stock for the three-month period ended March 31, 2018: Please refer to attachment 3.
- h. Receivables from related parties with amounts exceeding the lower of NT\$100 million or 20 percent of capital stock as of March 31, 2018: Please refer to attachment 5.

- i. Financial instruments and derivative transactions: None
- j. Intercompany relationships and significant intercompany transaction: Please refer to attachment 6.

(2) Information on investees

- A. Names, locations and related information of investees as of March 31, 2018 (excluding the investment in Mainland China): Please refer to attachment 4.
- B. Information at significant transactions
 - a. Financing provided to others for the three-month period ended March 31, 2018: None
 - b. Endorsement/Guarantee provided to others for the three-month period ended March 31, 2018: None
 - c. Securities held as of March 31, 2018: Please refer to attachment 2.
 - d. Individual securities acquired or disposed of with accumulated amount exceeding the lower of NT\$300 million or 20 percent of the capital stock for the three-month period ended March 31, 2018: None
 - e. Acquisition of individual real estate with amount exceeding the lower of NT\$300 million or 20 percent of the capital stock for the three-month period ended March 31, 2018: None
 - f. Disposal of individual real estate with amount exceeding the lower of NT\$300 million or 20 percent of the capital stock for the three-month period ended March 31, 2018: None
 - g. Related party transactions for purchases and sales amounts exceeding the lower of NT\$100 million or 20 percent of the capital stock for the three-month period ended March 31, 2018: Please refer to attachment 3.

Grape King Bio Ltd. and Subsidiaries

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(REVIEWED BUT UNAUDITED)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

- h. Receivables from related parties with amounts exceeding the lower of NT\$100 million or 20 percent of capital stock as of March 31, 2018: None.

- i. Financial instruments and derivative transactions: None

English Translation of Consolidated Financial Statements and Footnotes Originally Issued in Chinese

Grape King Bio Ltd. and Subsidiaries

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(REVIEWED BUT UNAUDITED)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

(3) Information on investments in mainland China:

Investee company name, main businesses and products, total amount of capital, method of investment, accumulated inflow and outflow of investments from Taiwan, net income (loss) of investee company, percentage of ownership, investment income (loss), book value of investments, cumulated inward remittance of earnings and limits on investment in Mainland China:

Amounts in Thousands of New Taiwan Dollars, Unless Specified Otherwise

Investee company	Main businesses and products	Total amount of paid-in capital	Method of investment (Note 1)	Accumulated Investment Outflows from Taiwan as at January 1, 2018	Investment Flows		Accumulated Investment Outflows from Taiwan as at March 31, 2018	Net Income (Loss) of Investee Company	Percentage of Direct or Indirect Ownership	Investment Profit(Loss) Recognized (Note 2)	Carrying Amount as at March 31, 2018	Accumulated Inward Remittance of Earnings as of March 31, 2018
					Outflow	Inflow						
Shanghai Grape King Enterprise Co., Ltd.	Manufacturing and selling capsule, tablet, related products and services.	US\$27,900 thousand	(Note 1(2)) (Note 3)	\$847,672 (USD27,350 thousand)	\$-	\$-	\$847,672 (USD 27,350 thousand)	\$43,829 (Note 2 (2)B)	100%	\$43,857 (Note 2(2)B)	\$635,728	\$-
Shanghai Yusong Co., Ltd.	Stock management and related services of the thermostatic fresh freezing warehouse.	US\$4,890 thousand	(Note 1(2)) (Note 4)	\$26,794 (USD878 thousand)	\$-	\$-	\$26,794 (USD878 thousand)	\$- (Note 2(3))	18.77%	\$- (Note 2(3))	\$16,640 (Note 2(3))	\$-

English Translation of Consolidated Financial Statements and Footnotes Originally Issued in Chinese

Grape King Bio Ltd. and Subsidiaries

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(REVIEWED BUT UNAUDITED)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

Shanghai Rivershine Ltd.	Food distribution (except grain), food packaging materials, cosmetics wholesale, import and export, commission agents (except auction), related products and services.	US\$150 thousand	(Note 1(2)) (Note 5)	\$4,060 (USD 150 thousand)	\$-	\$-	\$4,060 (USD 150 thousand)	\$(169) (Note 2(2)B)	100%	\$(169) (Note 2(2)B)	\$4,328	\$-
--------------------------	--	------------------	-------------------------	-------------------------------	-----	-----	-------------------------------	-------------------------	------	-------------------------	---------	-----

Accumulated investment in Mainland China as at March 31, 2018	Investment amounts authorized by Investment Commission, MOEA	Upper limit on investment
\$878,526	\$878,526	\$4,057,231

Note 1 : The methods for engaging in investment in Mainland China include the following:

- (1) Direct investment in Mainland China.
- (2) Indirectly investment in Mainland China through companies registered in a third region. (Please specify the name of the company in third region).
- (3) Other methods.

Note 2 : The investment income (loss) recognized in current period:

1. Please specify no investment income (loss) has been recognized due to the investment is still during development stage.
2. The investment income (loss) were determined based on the following basis:
 - (A) The financial report was audited and certified by an international accounting firm in cooperation with an R.O.C. accounting firm.
 - (B) The financial statements certificated by the CPA of the parent company in Taiwan.
 - (C) Others.
3. Recorded as financial assets at fair value through other comprehensive income.

Note 3 : The Company invested in Shanghai Grape King Enterprise Co, Ltd. through subsidiary GRAPE KING INTERNATIONAL INVESTMENT INC. (BVI).

Note 4 : The Company invested in Shanghai Yusong Co., Ltd. through Fu-Sheng International Inc. (SAMOA)

Note 5 : The Company indirectly invested in Shanghai Rivershine Ltd. through its subsidiary, GRAPE KING INTERNATIONAL INVESTMENT INC. (BVI).

Grape King Bio Ltd. and Subsidiaries

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(REVIEWED BUT UNAUDITED)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

14. Segment information

The Group determined its operating segments based on business activities with discrete financial information regularly reported through the Company's internal reporting protocols to the Company's chief operating decision maker. The Company is organized into business units based on its marketing channels and services. As of March 31, 2018 and 2017, the Company had the following segments: MLM (Multi-level marketing), Distributors, and OEM (Original Equipment Manufacturer).

No operating segments have been aggregated to form the above reportable operating segments.

Management monitors the operating results of its business units separately for the purpose of making decisions about resource allocation and performance assessment. Segment performance is evaluated based on operating profit or loss and is measured based on accounting policies consistent with those in the consolidated financial statements. However income taxes are managed on a group basis and are not allocated to operating segments.

Transfer prices between operating segment are on an arm's length basis in a manner similar to transactions with third parties.

(1) Income (loss), for reportable segments

For three-month period ended March 31, 2018

	MLM	Distribution	OEM	Subtotal	Adjustment/ elimination (Note)	Consolidated
Revenue						
External						
customer	\$1,584,326	\$58,351	\$289,749	\$1,932,426	\$-	\$1,932,426
Inter-segment	299,073	24,531	1,519	325,123	(325,123)	-
Total revenue	<u>\$1,883,399</u>	<u>\$82,882</u>	<u>\$291,268</u>	<u>\$2,257,549</u>	<u>\$(325,123)</u>	<u>\$1,932,426</u>
Segment						
profit	<u>\$411,509</u>	<u>\$(2,879)</u>	<u>\$65,892</u>	<u>\$474,522</u>	<u>\$-</u>	<u>\$474,522</u>

Grape King Bio Ltd. and Subsidiaries

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(REVIEWED BUT UNAUDITED)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

For three-month period ended March 31, 2017

	MLM	Distribution	OEM	Subtotal	Adjustment/ elimination (Note)	Consolidated
Revenue						
External						
customer	\$1,841,981	\$64,640	\$97,308	\$2,003,929	\$-	\$2,003,929
Inter-segment	315,778	26,461	1,591	343,830	(343,830)	-
Total revenue	<u>\$2,157,759</u>	<u>\$91,101</u>	<u>\$98,899</u>	<u>\$2,347,759</u>	<u>\$(343,830)</u>	<u>\$2,003,929</u>
Segment						
profit	<u>\$455,570</u>	<u>\$(3,090)</u>	<u>\$9,034</u>	<u>\$461,514</u>	<u>\$-</u>	<u>\$461,514</u>

Note:

Inter-segment revenue are eliminated on consolidation and recorded under the “adjustment and elimination” column. Other adjustments and eliminations, which has not significant influence, are not disclosed.

(2) Reconciliation of revenue, income.

(1) Revenue

	For three-month period ended March 31,	
	2018	2017
Total revenue	\$2,257,549	\$2,347,759
Other revenue	-	-
Elimination of inter-segment profit	(325,123)	(343,830)
Group revenue	<u>\$1,932,426</u>	<u>\$2,003,929</u>

Grape King Bio Ltd. and Subsidiaries

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(REVIEWED BUT UNAUDITED)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

(2) Profit or loss

	For three-month period ended March 31,	
	2018	2017
Total income (Loss)	\$474,522	\$461,514
Other income (Loss)	-	-
Elimination of inter-segment profit	-	-
Pre-tax income	\$474,522	\$461,514

English Translation of Consolidated Financial Statements Originally Issued in Chinese

Grape King Bio Ltd. and Subsidiaries
Endorsement/Guarantee Provided to Others
For the three-month period ended March 31, 2018

ATTACHMENT 1

(Amounts Expressed in Thousands of New Taiwan Dollars)

Endorsements or guarantees provider		Guaranteed Party		Limits on Endorsement/ Guarantee Amount Provided to Each Guaranteed Party(Note3)	Maximum Balance for the Period	Ending Balance	Amount Actually Drawn	Amount of Endorsement/ Guarantee secured by Properties	Ratio of Accumulated Endorsement/ Guarantee to Net Worth per Latest Financial Statements	Maximum Endorsement/ Guarantee Amount Allowed(Note3)	Endorsement provided by parent company to subsidiaries	Endorsement provided by subsidiaries to parent company	Endorsement provided to entities in China
No. (Note1)	Name	Company Name	Relationship (Note2)										
0	Grape King Bio Ltd.	Shanghai Grape King Enterprise Co., Ltd.	3	\$2,337,861	\$93,930	\$93,930	\$-	\$93,930	1.81%	\$2,493,718	Y	N	Y

Note1 : No.0 is for the parent company. Subsidiaries are numbered from Arabic numerals 1.

Note2 : The relationship between the guarantor of the endorsement and the object to be guaranteed is as follows:

- 1.business related parties
- 2.A company in which the public company directly holds more than 50% of ordinary shares.
- 3.The investee company with more than 50% of the shares held by the parent company and its subsidiaries.
- 4.The parent company directly holds more than 50% of the ordinary shares of the company or through subsidiaries indirectly hold more than 50% of the ordinary shares of the company.
- 5.Where a public company fulfills its contractual obligations by providing mutual endorsements/guarantees for another company in the same industry.
- 6.A company whose co-investment relationship is endorsed by its shareholders in proportion to their shareholding ratio.

Note3 : According to the Company's "Endorsement Procedures", the total amount of the guarantees endorsed by the Company is limited to 48% of the net value of the Company's most recent financial statements.
The guarantee limit for endorsement of a single enterprise is limited to 45% of the net value of the most recent financial statements.

English Translation of Consolidated Financial Statements Originally Issued in Chinese
 Grape King Bio Ltd. and Subsidiaries
 Securities held as of March 31, 2018 (excluding subsidiaries, associates and joint venture)

ATTACHMENT2

(Amounts in Thousands of New Taiwan Dollars, Unless Specified Otherwise)

Company Held Name	Marketable Securities Type and Name	Relationship with the Company	Financial Statement Account	As of March 31, 2018				Note	
				Shares/Units	Carrying Value	Percentage of Ownership	Fair Value		
Grape King Bio Ltd.	Fund	Fuh Hwa You Li Money Market	-	Financial assets at fair value through profit or loss, current	2,237,804.00	\$30,023		30,023	
		UPAMC James Bond Money Market	-	Financial assets at fair value through profit or loss, current	1,805,336.57	30,027		30,027	
		Hua Nan Kirin Money Market	-	Financial assets at fair value through profit or loss, current	3,359,170.90	40,036		40,036	
		Total				<u>100,086</u>		<u>100,086</u>	
Grape King Bio Ltd.	Stock	Fu-Sheng International Inc.(SAMOA)	-	Financial assets at fair value through other comprehensive ncome, noncurrent	917,700.00	\$28,008	18.77%	16,640	
		Hsin Tung Yang Co., Ltd.	-	Financial assets at fair value through other comprehensive ncome, noncurrent	2,000.00	20	-	24	
		Total		Financial assets at fair value through other comprehensive ncome, valuation adjustments		<u>(11,364)</u>		<u>-</u>	
						<u>\$16,664</u>		<u>\$16,664</u>	
Pro-partner Inc.	Fund	Nomura Taiwan Money Market	-	Financial assets at fair value through profit or loss, current	2,167,437.66	\$35,198		35,198	
		UPAMC James Bond Money Market	-	Financial assets at fair value through profit or loss, current	2,115,225.39	35,181		35,181	
		Total				<u>\$70,379</u>		<u>\$70,379</u>	

English Translation of Consolidated Financial Statements Originally Issued in Chinese

Grape King Bio Ltd. and Subsidiaries

Related party transactions for purchases and sales amounts exceeding the lower of NT\$100 million or 20 percent of the capital stock for the three-month period ended March 31, 2018

ATTACHMENT3

(Amounts in Thousands of New Taiwan Dollars, Unless Specified Otherwise)

Company Name	Related Party	Nature of Relationships	Transaction Details				Abnormal Transaction(note1)		Notes/Accounts Payable or Receivable		Note
			Purchases/Sales	Amount	Percentage of total Purchases (Sale)	Payment Terms	Unit Price	Payment Terms	Ending Balance	Percentage of total receivables (payable)	
Grape King Bio Ltd.	Pro-partner Inc.	Subsidiary	Sales	\$299,073	79.36%	Net 30 days after monthly closing	By contract	-	\$125,809	60.52%	2
Pro-partner Inc.	Grape King Bio Ltd.	Parent Company	Purchases	\$299,073	100.00%	Net 30 days after monthly closing	By contract	-	\$(125,809)	97.85%	2

Note1 : If the terms of transactions with the related parties are different from normal terms, the difference and the reason for the difference should be declared in the column of unit price or credit period.

Note2 : The transactions have been eliminated in the consolidated financial statements.

English Translation of Consolidated Financial Statements Originally Issued in Chinese

Grape King Bio Ltd. and Subsidiaries

Names, locations and related information of investees as of March 31, 2018 (excluding the investment in Mainland China)

ATTACHMENT 4

(Amounts in Thousands of New Taiwan Dollars)

Investor	Investee	Location	Main Business	Original Investment Amount		Balance as of March 31, 2018			Net Income (Losses) of the Investee	Share of Profits/Losses of Investee	Note
				March 31, 2018	December 31, 2017	Shares	Percentage of Ownership	Book Value			
Grape King Bio Ltd.	GRAPE KING INTERNATIONAL INVESTMENT INC.(BVI)	BVI	Investment activities	\$1,198,018	\$1,198,018	24,890,000	100.00%	\$685,943	\$42,596	\$42,624 (Note1)	Subsidiary
	Pro-partner Inc.	Taoyuan City, Taiwan	Import and selling of health food, drink, cosmetics, sports apparatus, cleaning the articles, etc.	15,000	15,000	10,560,000	60.00%	1,856,078	288,688	172,894 (Note1)	Subsidiary
	Rivershine Ltd.	Taoyuan City, Taiwan	Import and selling of health food, drink, daily commodities, appliances, etc.	30,000	30,000	3,000,000	100.00%	27,386	(1,024)	(1,024)	Subsidiary
			Total					<u>\$2,569,407</u>		<u>\$214,494</u>	

Note1 : The effect from the unrealized profit of the downstream transactions on income tax, which is NT\$(290) thousand has been adjusted.

Note2 : The book value at the end of the period and the current investment gain(loss) recognized have been eliminated in the consolidated financial statement.

English Translation of Consolidated Financial Statements Originally Issued in Chinese

Grape King Bio Ltd. and Subsidiaries

Receivables from related parties with amounts exceeding the lower of NT\$100 million or 20 percent of capital stock as of March 31, 2018

ATTACHMENT 5

(Amounts in Thousands of New Taiwan Dollars, Unless Specified Otherwise)

Company Name	Related Party	Nature of Relationships	Ending Balance (Note)		Turnover Rate	Overdue		Amounts Received in Subsequent Period	Recognized as Allowance for Bad Debts
						Amount	Action Taken		
Grape King Bio Ltd.	Pro-partner Inc.	Subsidiary	Accounts Receivable -Related Parties	<u>\$125,809</u>	9.42	<u>\$-</u>	-	<u>\$125,809</u>	<u>\$-</u>

Note : The transactions have been eliminated in the consolidated financial statements.

English Translation of Consolidated Financial Statements Originally Issued in Chinese

Grape King Bio Ltd. and Subsidiaries

Intercompany relationships and significant intercompany transaction for the three-month period ended March 31, 2018

ATTACHMENT6

(Amounts expressed in Thousands of New Taiwan Dollars)

No. (Note1)	Company Name	Counterparty	Nature of Relations (Note2)	Intercompany Transactions			
				Financial Statements Item	Amount	Terms	Percentage of Consolidated Total Revenue or Total Assets (Note3)
0	Grape King Bio Ltd.	Pro-partner Inc.	1	Sales	\$299,073	The price by contract	15.48%
0	Grape King Bio Ltd.	Pro-partner Inc.	1	Accounts Receivable	\$125,809	The price by contract	1.25%

Note1 : No.0 is for the parent company. Subsidiaries are numbered from Arabic numerals 1.

Note2 : There are three types of relations between the parent company and the subsidiaries. Only categories should be identified.(There is no need to declare the same interaction between the parent company and the subsidiary, or the same transaction among subsidiaries repeatedly. For example,if the parent company has declared the transaction from parent company to subsidiary, the subsidiary need not repeatedly declare the same transaction. If the transaction is between subsidiaries, when one subsidiary has declared the transaction, the other subsidiary doesn't need to declare the same transaction.)

(1) represents the transactions from parent company to subsidiary.

(2) represents the transactions from subsidiary company to parent.

(3) represents the transactions between subsidiaries.

Note3 : When calculating the amount of transaction as a proportion of the consolidated revenue or assets, if it is recognized as items of assets or liabilities, the ending balance should be divided by the consolidated assets: if it is recognized as income or loss, the midterm accumulated amount should be divided by the consolidated.

Note4 : The so-called significant transaction refers to those amount reaching NT\$100 million or over 20% of the paid-in capital of the parent company.